CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10016683,100166833,3,F,,20160316,20140317,20160316,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-20545059,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160316,,CN,US,AT,EFAVIRENZ,Drug interaction;Dyslipidaemia;Gastrointestinal toxicity;Hepatotoxicity;Hypersensitivity;Maternal exposure during pregnancy;Nephropathy toxic;Neurotoxicity;Off label use;Toxicity to various agents;Treatment failure;Virologic failure,100166833,OT,,,,,,,,,100166833,1,HIV infection
10095098,100950983,3,F,,20160129,20140422,20160205,EXP,,CA-ABBVIE-14K-028-1226359-00,ABBVIE,,54,YR,,M,Y,,,20160205,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,100950983,OT,,,,,,,,,100950983,1,Product used for unknown indication
10143929,101439296,6,F,,20160218,20140430,20160219,EXP,,CA-009507513-1007USA00479,MERCK,,54,YR,,M,Y,,,20160219,,OT,US,CA,SUSTIVA,Depression;Drug interaction,101439296,OT,,,,,,,,,101439296,1,Product used for unknown indication
10517572,105175724,4,F,,20160307,20141014,20160308,EXP,,CA-ABBVIE-14P-028-1294263-00,ABBVIE,"PFEFFER G, COTE H, MEZEI M, ET AL. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009?73 (1):71-72.",52,YR,,M,Y,,,20160308,,MD,COUNTRY NOT SPECIFIED,CA,EFAVIRENZ,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,105175724,OT,,,105175724,2,200802,,,,105175724,1,Antiretroviral therapy
10525523,105255233,3,F,20140902,20160304,20141017,20160310,EXP,,UG-GILEAD-2014-0118171,GILEAD,,20,YR,A,M,Y,,,20160310,,MD,UG,UG,EFAVIRENZ,Bladder outlet obstruction;Glomerulonephritis,105255233,LT,,,105255233,1,20140811,20140909,,,105255233,1,HIV infection
10529194,105291948,8,F,2014,20160322,20141020,20160331,EXP,FR-ANSM-PV20140326,FR-GILEAD-2014-0118805,GILEAD,,58,YR,A,M,Y,74,KG,20160331,,OT,FR,FR,EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE/EFAVIRENZ,Arrhythmia;Atrioventricular block complete;Bradycardia;Bundle branch block;Conduction disorder;Syncope,105291948,OT,,,105291948,1,20140829,201502,,,105291948,1,Hepatitis C
10782797,107827973,3,F,,20160316,20150210,20160316,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006291,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160316,,OT,GB,GB,EFAVIRENZ,Foetal exposure during pregnancy;Off label use;Ultrasound antenatal screen abnormal,107827973,OT,,,107827973,1,20140916,20141031,,,107827973,1,Antiretroviral therapy
10978477,109784773,3,F,20150112,20160315,20150402,20160318,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-019001,BRISTOL MYERS SQUIBB,,12,YR,,M,Y,,,20160318,,OT,KE,KE,EFAVIRENZ,Gastroenteritis,109784773,HO,,,,,,,,,109784773,1,Antiretroviral therapy
11054474,110544742,2,F,,20160117,20150422,20160201,EXP,,CH-CIPLA LTD.-2015CH03145,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2015?1 TO 20",,,,,Y,,,20160201,,OT,CH,GB,Efavirenz,Hepatic steatosis;Hepatitis C,110544742,DE,,,,,,,,,110544742,1,HIV infection
11054477,110544772,2,F,,20160117,20150422,20160201,EXP,,CH-CIPLA LTD.-2015CH03142,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2015?1 TO 20",,,,,Y,,,20160201,,OT,CH,GB,Efavirenz,Lactic acidosis,110544772,DE,,,,,,,,,110544772,1,HIV infection
11093886,110938863,3,F,,20160316,20150506,20160323,EXP,,GB-BMSGILMSD-2015-0151479,GILEAD,"BULMAN J, TEO SY, PAGE E, SHILLITO J, EVANS A. AN UNCOMMON CAUSE OF ANAEMIA IN PREGNANCY: A CASE REPORT OF EMTRICITABINE-INDUCED PURE RED CELL APLASIA. POSTER PRESENTATION. 2015?UNK:UNK",39,YR,A,F,Y,,,20160323,,OT,GB,GB,EFAVIRENZ,Aplasia pure red cell;Maternal exposure during pregnancy;Off label use,110938863,OT,,,,,,,,,110938863,1,HIV infection
11166253,111662532,2,F,200811,20160303,20150605,20160314,EXP,,ES-CIPLA LTD.-2015ES04334,CIPLA,"MIRODDI M, CALAPAI G, CASCIARO M, CALAPAI F, NAVARRA M, GANGEMI S. MONTELUKAST-INDUCED ADVERSE DRUG REACTIONS: A REVIEW OF CASE REPORTS IN THE LITERATURE. PHARMACOLOGY. 2014?94:60 TO 70",,,,,Y,,,20160314,,OT,IT,ES,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Abnormal dreams;Confusional state;Disturbance in attention;Drug interaction;Drug intolerance;Irritability;Nightmare;Sleep disorder,111662532,OT,,,111662532,1,200707,201201,,,111662532,1,HIV infection
11225710,112257103,3,F,20150310,20151221,20150629,20160105,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-024150,BRISTOL MYERS SQUIBB,,37,YR,,M,Y,,,20160105,,CN,US,ZW,EFAVIRENZ,Gastroenteritis;Tuberculosis,112257103,OT,,,112257103,1,20150226,20150302,,,112257103,1,HIV infection
11255828,112558283,3,F,20150415,20160308,20150709,20160311,EXP,,KE-GILEAD-2015-0161643,GILEAD,,43,YR,A,F,Y,67.9,KG,20160311,,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Blood creatinine increased;Hyperkalaemia,112558283,HO,,,112558283,1,20150318,20150416,,,112558283,1,Product used for unknown indication
11339895,113398952,2,F,,20160229,20150805,20160313,EXP,,US-CIPLA LTD.-2015US06208,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV 1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Disease recurrence;Drug resistance;Virologic failure,113398952,OT,,,,,,,,,113398952,1,HIV infection
11339946,113399462,2,F,,20160229,20150805,20160313,EXP,,US-CIPLA LTD.-2015US06211,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Renal tubular disorder,113399462,OT,,,,,,,,,113399462,1,HIV infection
11407819,114078193,3,F,20080422,20160316,20150821,20160315,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-055387,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20160315,,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Off label use;Pregnancy on contraceptive,114078193,OT,,,114078193,1,200508,,,,114078193,1,Product used for unknown indication
11641525,116415255,5,F,20150409,20160104,20151019,20160108,EXP,,ZA-GILEAD-2015-0176566,GILEAD,,35,YR,A,F,Y,69.5,KG,20160108,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Delirium;Gastroenteritis,116415255,OT,,,116415255,1,20141007,,,,116415255,1,HIV infection
11644114,116441143,3,F,201402,20151218,20151020,20160105,EXP,,MX-VIIV HEALTHCARE LIMITED-MX2015148662,VIIV,,37,YR,,F,Y,,,20160105,,MD,MX,MX,EFAVIRENZ W/ZIDOVUDINE,Anaemia;Blood creatinine increased;Creatinine renal clearance decreased,116441143,OT,,,116441143,1,201309,201309,,,116441143,1,HIV infection
11703759,117037592,2,F,20120612,20160316,20151106,20160316,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-19034917,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20160316,,OT,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Off label use,117037592,OT,,,117037592,1,20101007,,,,117037592,1,Antiretroviral therapy
11708334,117083342,2,F,20120331,20160315,20151107,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17309105,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20160315,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Off label use,117083342,OT,,,117083342,1,20110920,,,,117083342,1,Antiretroviral therapy
11708336,117083363,3,F,20151026,20151125,20151107,20160118,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075218,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,95,KG,20160118,,OT,BR,BR,EFAVIRENZ,Hypotension;Maternal exposure during pregnancy;Uterine haemorrhage,117083363,OT,,,117083363,1,20150828,,,,117083363,1,HIV infection
11713534,117135342,2,F,20121127,20160315,20151109,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17234345,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20160315,,CN,US,GB,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Maternal exposure during pregnancy;Off label use,117135342,OT,,,,,,,,,117135342,1,Antiretroviral therapy
11713594,117135942,2,F,20121127,20160315,20151109,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17201724,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20160315,,CN,US,GB,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Maternal exposure during pregnancy;Off label use,117135942,OT,,,,,,,,,117135942,1,Antiretroviral therapy
11714021,117140212,2,F,20131017,20160217,20151109,20160222,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-19804897,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,66.5,KG,20160222,,OT,MW,MW,EFAVIRENZ,Death;Maternal exposure during pregnancy;Premature delivery,117140212,DE,,,117140212,1,20080917,20120926,,,117140212,1,HIV infection
11721294,117212942,2,F,,20160202,20151111,20160202,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15386592,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20160202,,OT,GB,US,SUSTIVA,Drug interaction;Normal newborn;Pregnancy with implant contraceptive,,,,,117212942,1,200701,,,,117212942,1,Antiretroviral therapy
11726493,117264932,2,F,,20160202,20151112,20160209,PER,,US-009507513-1011USA03114,MERCK,,33,YR,,F,Y,,,20160209,,CN,US,US,SUSTIVA,Drug interaction;Normal newborn;Pregnancy with implant contraceptive,,,,,117264932,1,200701,,,,117264932,1,Antiretroviral therapy
11730095,117300953,3,F,200508,20160202,20151112,20160210,EXP,,ES-GILEAD-2015-0181587,GILEAD,,52,YR,A,F,Y,52,KG,20160210,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Creatinine renal clearance decreased;Insomnia;Osteopenia;Osteoporosis,117300953,OT,,,117300953,1,200507,201312,,,117300953,1,HIV infection
11744738,117447384,4,F,2008,20151230,20151116,20160111,EXP,,GB-009507513-1001USA00481,MERCK,,33,YR,,F,Y,,,20160111,,OT,GB,GB,EFAVIRENZ,Labelled drug-drug interaction medication error;Normal newborn;Pregnancy with implant contraceptive,117447384,OT,,,117447384,2,20040811,20070716,,,117447384,1,HIV infection
11762825,117628252,2,F,,20160316,20151120,20160316,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17372277,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160316,,CN,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Off label use,117628252,OT,,,,,,,,,117628252,1,Antiretroviral therapy
11762838,117628382,2,F,20130411,20160316,20151120,20160316,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18861518,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20160316,,OT,GB,GB,EFAVIRENZ,Live birth;Maternal exposure during pregnancy;Off label use;Premature delivery;Renal impairment,117628382,OT,,,117628382,1,20110102,,,,117628382,1,Antiretroviral therapy
11770388,117703884,4,F,20140805,20160301,20151123,20160303,EXP,,UG-GILEAD-2015-0183893,GILEAD,,34,YR,A,F,Y,,,20160303,,MD,UG,UG,EFAVIRENZ,Anaemia;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,117703884,HO,,,117703884,1,20140729,20140822,,,117703884,1,HIV infection
11772370,117723702,2,F,20140805,20160107,20151124,20160112,EXP,,UG-GLAXOSMITHKLINE-UG2015167028,GLAXOSMITHKLINE,,34,YR,,F,Y,,,20160112,,MD,UG,UG,Efavirenz,Anaemia;Kaposi's sarcoma,117723702,HO,,,117723702,1,20140729,20140822,,,117723702,1,HIV infection
11772506,117725064,4,F,20140805,20160301,20151124,20160307,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2015167028,VIIV,,34,YR,,F,Y,,,20160307,,MD,UG,UG,Efavirenz,Anaemia;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,117725064,DE,,,117725064,1,20140729,20140822,,,117725064,1,HIV infection
11796521,117965212,2,F,,20160114,20151203,20160120,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2015171688,VIIV,"LO, CHANG HAN AND LIN, TE YU MD. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. RESPIRATORY CARE. 2014?59:160-162",27,YR,,M,Y,,,20160120,,MD,TW,TW,Efavirenz,Immune reconstitution inflammatory syndrome,117965212,HO,,,,,,,,,117965212,1,HIV infection
11796524,117965242,2,F,,20160114,20151203,20160120,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2015GSK170615,VIIV,,27,YR,,M,Y,,,20160120,,MD,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung infiltration;Pneumocystis jirovecii pneumonia;Pyrexia;Rales,117965242,HO,,,,,,,,,117965242,1,HIV infection
11796615,117966152,2,F,,20160114,20151203,20160120,EXP,,TW-GLAXOSMITHKLINE-TW2015GSK170615,GLAXOSMITHKLINE,,27,YR,,M,Y,,,20160120,,MD,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung infiltration;Pneumocystis jirovecii pneumonia;Pyrexia;Rales,117966152,OT,,,,,,,,,117966152,1,HIV infection
11796666,117966662,2,F,,20160114,20151203,20160120,EXP,,TW-GLAXOSMITHKLINE-TW2015171688,GLAXOSMITHKLINE,"LO, CHANG HAN AND LIN, TE YU MD. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. RESPIRATORY CARE. 2014?59:160-162",27,YR,,M,Y,,,20160120,,MD,TW,TW,Efavirenz,Immune reconstitution inflammatory syndrome,117966662,HO,,,,,,,,,117966662,1,HIV infection
11806344,118063442,2,F,,20160114,20151207,20160120,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2015GSK170585,VIIV,"LO CH, ET AL.. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME.. RESPIRATORY CARE. 2014?59?10:E160-E162",27,YR,,M,Y,,,20160120,,OT,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung disorder;Pyrexia,118063442,HO,,,,,,,,,118063442,1,HIV infection
11806574,118065742,2,F,,20160114,20151207,20160120,EXP,,TW-GLAXOSMITHKLINE-TW2015GSK170585,GLAXOSMITHKLINE,"LO CH, ET AL.. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME.. RESPIRATORY CARE. 2014?59?10:E160-E162",27,YR,,M,Y,,,20160120,,OT,TW,TW,Efavirenz,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung disorder;Pyrexia,118065742,OT,,,,,,,,,118065742,1,HIV infection
11812699,118126992,2,F,,20160315,20151208,20160315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17196734,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20160315,,OT,GB,GB,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy;Off label use;Premature delivery;Premature rupture of membranes;Uterine leiomyoma,118126992,OT,,,,,,,,,118126992,1,HIV infection
11813500,118135002,2,F,1999,20160104,20151209,20160105,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12428462,BRISTOL MYERS SQUIBB,,,,,F,Y,.16,KG,20160105,,CN,FR,FR,EFAVIRENZ,Bone development abnormal;Congenital musculoskeletal anomaly;Congenital pulmonary valve disorder;Foetal exposure during pregnancy;Pulmonary malformation,118135002,OT,,,118135002,1,1999,,,,118135002,1,Product used for unknown indication
11816005,118160054,4,F,,20160202,20151209,20160205,EXP,,US-009507513-1011USA03112,MERCK,,35,YR,,F,Y,,,20160205,,OT,US,US,EFAVIRENZ,Abortion induced;Drug interaction;Pregnancy with implant contraceptive,118160054,OT,,,,,,,,,118160054,1,Antiretroviral therapy
11824708,118247083,3,F,20151028,20160222,20151210,20160329,EXP,,UG-GILEAD-2015-0186293,GILEAD,,49,YR,A,M,Y,69,KG,20160329,,MD,UG,UG,EFAVIRENZ,Road traffic accident;Soft tissue injury,118247083,HO,,,118247083,1,20130910,,,,118247083,1,HIV infection
11824709,118247092,2,F,20151112,20160107,20151210,20160112,EXP,,GB-GILEAD-2015-0186285,GILEAD,,34,YR,A,M,Y,74.2,KG,20160112,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Generalised tonic-clonic seizure,118247092,OT,,,118247092,1,20111111,,,,118247092,1,HIV infection
11827166,118271662,2,F,,20160202,20151211,20160209,EXP,,GB-009507513-0803USA04049,MERCK,,,,,F,Y,,,20160209,,OT,GB,GB,EFAVIRENZ,Drug interaction;Pregnancy with implant contraceptive,118271662,OT,,,118271662,2,2006,,,,118271662,1,Retroviral infection
11834437,118344372,2,F,20150709,20151231,20151214,20160108,PER,,US-JNJFOC-20151124956,JANSSEN,,48,YR,A,F,Y,103.42,KG,20160108,,CN,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Pulmonary embolism;Vaginal haemorrhage,118344372,HO,,,118344372,1,20130401,20150709,,,118344372,1,Thrombosis
11838750,118387502,2,F,20150925,20160301,20151215,20160307,EXP,,US-GILEAD-2015-0187288,GILEAD,,35,YR,A,F,Y,93.88,KG,20160307,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure via body fluid;Maternal exposure during pregnancy,118387502,OT,,,118387502,1,20150624,,,,118387502,1,Prophylaxis
11842570,118425702,2,F,20080103,20160301,20151216,20160303,EXP,,AU-009507513-1001USA00195B1,MERCK,,12,MON,,F,Y,3.18,KG,20160303,,CN,AU,AU,EFAVIRENZ,Congenital tricuspid valve stenosis;Foetal exposure during pregnancy;Hepatitis C;Hypoplastic right heart syndrome,118425702,LT,,,118425702,1,,20080512,,,118425702,1,Product used for unknown indication
11843123,118431232,2,F,,20160324,20151216,20160324,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-15212673,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160324,,OT,BR,BR,EFAVIRENZ,Congenital hydronephrosis;Congenital vesicoureteric reflux;Foetal exposure during pregnancy,118431232,OT,,,118431232,1,20041219,20040701,,,118431232,1,Product used for unknown indication
11844171,118441712,2,F,20050804,20160225,20151217,20160225,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13112461,BRISTOL MYERS SQUIBB,,15,YR,,F,Y,,,20160225,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy,118441712,OT,,,118441712,1,19991115,20050801,,,118441712,1,HIV infection
11853482,118534822,2,F,20080208,20160202,20151218,20160202,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-14092738,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,56.7,KG,20160202,,CN,US,AR,BLINDED EFAVIRENZ,Abortion spontaneous;Pregnancy on oral contraceptive,118534822,OT,,,118534822,1,20060403,20080203,,,118534822,1,HIV infection
11866706,118667062,2,F,,20160122,20151224,20160202,EXP,,GB-009507513-1512GBR012323,MERCK,,28,YR,,M,Y,,,20160202,,CN,US,GB,EFAVIRENZ,Mental disorder,118667062,OT,,,118667062,1,20150601,,,,118667062,1,Product used for unknown indication
11866971,118669712,2,F,20140825,20160225,20151224,20160225,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21576756,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20160225,,OT,BW,BW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Menorrhagia;Uterine dilation and curettage,118669712,OT,,,118669712,1,20110624,20140806,,,118669712,1,Antiretroviral therapy
11877375,118773752,2,F,,20160201,20151229,20160211,EXP,,GB-BMSGILMSD-2015-0189399,GILEAD,,33,YR,A,M,Y,,,20160211,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder,118773752,OT,,,,,,,,,118773752,1,HIV infection
11879089,118790892,2,F,20151215,20160127,20151230,20160201,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-091778,BRISTOL MYERS SQUIBB,,37,YR,,M,Y,,,20160201,,OT,UG,UG,EFAVIRENZ,Bacteraemia;Headache;Malaise;Neck pain;Pyrexia;Vision blurred,118790892,OT,,,118790892,1,20131128,20141106,,,118790892,1,HIV infection
11882849,118828492,2,F,20140128,20160114,20151231,20160118,EXP,,NG-GILEAD-2015-0190051,GILEAD,,52,YR,A,M,Y,,,20160118,,MD,NG,NG,EFAVIRENZ,Intestinal obstruction,118828492,OT,,,118828492,1,20130201,,,,118828492,1,HIV infection
11883068,118830682,2,F,,20160201,20151231,20160210,EXP,,GB-GILEAD-2015-0190541,GILEAD,,52,YR,A,M,Y,,,20160210,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug intolerance,118830682,OT,,,,,,,,,118830682,1,HIV infection
11883136,118831362,2,F,,20160201,20151231,20160211,EXP,,GB-GILEAD-2015-0190578,GILEAD,,42,YR,A,M,Y,,,20160211,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychiatric symptom,118831362,OT,,,,,,,,,118831362,1,HIV infection
11883137,118831372,2,F,,20160201,20151231,20160212,EXP,,GB-009507513-1512GBR014567,MERCK,,41,YR,,F,Y,,,20160212,,CN,US,GB,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Virologic failure,118831372,OT,,,118831372,1,20151001,20151001,,,118831372,1,HIV infection
11883161,118831612,2,F,,20160201,20151231,20160211,EXP,,GB-BMSGILMSD-2015-0190543,GILEAD,,32,YR,A,F,Y,,,20160211,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder,118831612,OT,,,,,,,,,118831612,1,HIV infection
11885581,118855811,1,I,20010430,20010830,20160104,20160104,EXP,,FR-009507513-01096030,MERCK,,38,YR,,F,Y,55,KG,20160104,,CN,US,FR,SUSTIVA,Bradycardia;Caesarean section;Escherichia pyelonephritis;Exposure during pregnancy;Lipodystrophy acquired;Live birth;Pregnancy;Pyelonephritis;Pyrexia,118855811,HO,,,118855811,1,20010430,20001102,,,118855811,1,HIV infection
11887494,118874941,1,I,,20151221,20160105,20160105,EXP,,PHHY2015TH171174,SANDOZ,"CHITASOMBAT MN, WATTANATRANON D.. DISSEMINATED MYCOBACTERIUM SIMIAE WITH PELVIC MALAKOPLAKIA IN AN AIDS PATIENT.. CLIN-MED-INSIGHTS-CASE-REP. 2015?8:89-91",3,DEC,,F,Y,,,20160105,,OT,TH,TH,EFAVIRENZ,Mycobacterial infection,118874941,OT,,,,,,,,,118874941,1,Acquired immunodeficiency syndrome
11887500,118875001,1,I,,20151221,20160105,20160105,EXP,,PHHY2015TH169783,SANDOZ,"CHITASOMBAT MN, WATTANATRANON D.. DISSEMINATED MYCOBACTERIUM SIMIAE WITH PELVIC MALAKOPLAKIA IN AN AIDS PATIENT.. CLIN-MED-INSIGHTS-CASE-REP. 2015?8:89-91",3,DEC,,F,Y,,,20160105,,OT,TH,TH,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Malacoplakia vesicae;Transaminases increased,118875001,OT,,,,,,,,,118875001,1,Acquired immunodeficiency syndrome
11888519,118885191,1,I,20010430,20001102,20160105,20160105,EXP,,FR-009507513-1601FRA000401,MERCK,,38,YR,,F,Y,55,KG,20160105,,CN,US,FR,SUSTIVA,Bradycardia;Caesarean section;Escherichia pyelonephritis;Exposure during pregnancy;Lipodystrophy acquired;Live birth;Pregnancy;Pyelonephritis;Pyrexia,118885191,OT,,,118885191,1,20010430,20001102,,,118885191,1,HIV infection
11888922,118889222,2,F,,20151231,20160105,20160128,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015GSK183980,VIIV,,,,,M,Y,,,20160128,,OT,GB,GB,Efavirenz,Death,118889222,DE,,,,,,,,,118889222,1,Product used for unknown indication
11888924,118889241,1,I,,20151228,20160105,20160105,EXP,,RS-VIIV HEALTHCARE LIMITED-RS2015GSK184370,VIIV,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC DJ.. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: CASE REPORT. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASE. 2016?42:40-42",28,YR,,M,Y,,,20160105,,OT,RS,RS,Efavirenz,CD4 lymphocytes decreased;General physical health deterioration;Immune reconstitution inflammatory syndrome;Pyrexia,118889241,HO,,,,,,,,,118889241,1,HIV infection
11889632,118896321,1,I,,20151225,20160105,20160105,EXP,,GB-GILEAD-2015-0190463,GILEAD,,1,DY,N,M,Y,1.92,KG,20160105,,MD,GB,GB,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction,118896321,OT,,,118896321,1,20060825,20061010,,,118896321,1,Product used for unknown indication
11890270,118902701,1,I,,20151228,20160105,20160105,EXP,,RS-GLAXOSMITHKLINE-RS2015GSK184370,GLAXOSMITHKLINE,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC DJ.. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: CASE REPORT. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASE. 2016?42:40-42",28,YR,,M,Y,,,20160105,,OT,RS,RS,Efavirenz,CD4 lymphocytes decreased;General physical health deterioration;Immune reconstitution inflammatory syndrome;Pyrexia,118902701,HO,,,,,,,,,118902701,1,HIV infection
11891040,118910401,1,I,,20151222,20160106,20160106,EXP,,US-CIPLA LTD.-2015US09995,CIPLA,"SMITH K, GOMES D, NIXON D AND FULCO P. THE USE OF UNBOOSTED DARUNAVIR IN THE SETTING OF RITONAVIR INTOLERANCE: THREE CASE REPORTS. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2015?1-6",,,,,Y,,,20160106,,OT,US,US,Efavirenz,Abdominal discomfort;Drug dose omission;Treatment failure;Vomiting,118910401,OT,,,,,,,,,118910401,1,HIV infection
11893181,118931811,1,I,,20151224,20160106,20160106,EXP,,PHHY2015US171782,SANDOZ,"WOOD BR, LACY JM, JOHNSTON C, WEIGLE DS, DHANIREDDY S.. ADRENAL INSUFFICIENCY AS A RESULT OF RITONAVIR AND EXOGENOUS STEROID EXPOSURE : REPORT OF 6 CASES AND RECOMMENDATION FOR MANAGEMENT.. J-INT-ASSOC-PROVID-AIDS-CARE. 2015?14(4):300-05",66,YR,,M,Y,,,20160106,,OT,US,US,EFAVIRENZ,Adrenal insufficiency;Clostridium difficile colitis;Cushing's syndrome;Drug interaction,118931811,OT,,,,,,,,,118931811,1,Chronic obstructive pulmonary disease
11893467,118934672,2,F,,20160105,20160106,20160118,PER,,US-APOTEX-2016AP005040,APOTEX,"WOOD BR, LACY JM, JOHNSTON C, WEIGLE DS, DHANIREDDY S.. ADRENAL INSUFFICIENCY AS A RESULT OF RITONAVIR AND EXOGENOUS STEROID EXPOSURE : REPORT OF 6 CASES AND RECOMMENDATION FOR MANAGEMENT.. J-INT-ASSOC-PROVID-AIDS-CARE. 2015?14(4):300-305",66,YR,,M,Y,,,20160118,,MD,US,US,EFAVIRENZ,Adrenal insufficiency;Cushing's syndrome;Drug interaction,118934672,OT,,,,,,,,,118934672,1,Chronic obstructive pulmonary disease
11893597,118935972,2,F,201512,20160108,20160106,20160115,EXP,,US-BMSGILMSD-2015-0190585,GILEAD,,55,YR,A,M,Y,,,20160115,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Appendicitis;Surgery,118935972,OT,,,,,,,,,118935972,1,HIV infection
11898828,118988281,1,I,,20100618,20160108,20160108,EXP,,US-009507513-1006USA04439B1,MERCK,,,,,,Y,,,20160108,,CN,US,US,SUSTIVA,Foetal exposure during pregnancy;Hypospadias,118988281,CA,,,,,,,,,,,
11899591,118995911,1,I,2015,20150720,20160108,20160108,PER,,US-ABBVIE-15P-163-1431302-00,ABBVIE,,50,YR,,F,Y,,,20160108,,CN,US,US,EFAVIRENZ,Drug dispensing error;Drug prescribing error;Fatigue,,,,,118995911,1,201505,,,,118995911,1,Hepatitis C
11903436,119034361,1,I,20150825,20150827,20160108,20160108,PER,,US-ABBVIE-15P-163-1453660-00,ABBVIE,,59,YR,,M,Y,,,20160108,,CN,COUNTRY NOT SPECIFIED,US,SUSTIVA,Blood urine present;Dysuria;Pyrexia,,,,,119034361,1,20150618,,,,119034361,1,Hepatitis C
11903551,119035512,2,F,,20151231,20160108,20160109,EXP,,US-GILEAD-2016-0191873,GILEAD,,34,YR,A,M,Y,,,20160108,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Hallucination;Headache;Nausea;Personality change;Unevaluable event,119035512,OT,,,119035512,1,2013,2013,,,119035512,1,HIV infection
11911498,119114981,1,I,20000606,20000620,20160112,20160112,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0501,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,,,20160112,,CN,US,US,EFAVIRENZ,Abortion induced;Pregnancy,119114981,OT,,,119114981,1,19990709,,,,119114981,1,HIV infection
11916239,119162391,1,I,20000705,20000710,20160114,20160114,EXP,,US-VIIV HEALTHCARE LIMITED-A0124113A,VIIV,,42,YR,,M,Y,,,20160114,,CN,US,US,SUSTIVA,Fatigue;Hypersensitivity;Influenza like illness;Pruritus;Pyrexia;Rash generalised,,,,,119162391,1,20000613,20000710,,,119162391,1,HIV infection
11918053,119180531,1,I,,20160104,20160114,20160114,EXP,,US-GILEAD-2016-0191274,GILEAD,,61,YR,A,M,Y,,,20160114,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,119180531,OT,,,,,,,,,119180531,1,HIV infection
11921961,119219611,1,I,201512,20160108,20160115,20160115,EXP,,US-GILEAD-2016-0192083,GILEAD,,64,YR,A,F,Y,,,20160115,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cough;Lower respiratory tract infection,119219611,OT,,,,,,,,,119219611,1,Acquired immunodeficiency syndrome
11921964,119219641,1,I,2009,20160108,20160115,20160115,EXP,,US-GILEAD-2016-0192094,GILEAD,,77,YR,E,M,Y,,,20160115,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,119219641,OT,,,,,,,,,119219641,1,HIV infection
11921989,119219891,1,I,,20160108,20160115,20160115,EXP,,US-GILEAD-2016-0191932,GILEAD,,51,YR,A,M,Y,,,20160115,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Varicose vein,119219891,HO,,,119219891,1,2010,201512,,,119219891,1,HIV infection
11922034,119220342,2,F,2015,20160121,20160115,20160127,EXP,,US-GILEAD-2016-0191910,GILEAD,,63,YR,A,M,Y,,,20160127,,MD,US,US,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthralgia;Candida infection;Dysphagia;Nausea;Oesophagitis;Oral fungal infection;Pyrexia;Viral infection;Vomiting,119220342,HO,,,119220342,1,20150501,,,,119220342,1,HIV infection
11922304,119223041,1,I,,20160112,20160115,20160115,EXP,,US-GILEAD-2016-0192491,GILEAD,,56,YR,A,M,Y,,,20160115,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood gases abnormal;Mechanical ventilation,119223041,DS,,,,,,,,,119223041,1,Product used for unknown indication
11924828,119248282,2,F,20160112,20160129,20160118,20160202,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2016GSK005769,VIIV,,0,DY,,M,Y,1.96,KG,20160202,,MD,BR,BR,Efavirenz,Underweight,119248282,LT,,,119248282,1,20151113,20160111,,,119248282,1,Antiretroviral therapy
11926339,119263391,1,I,,20160112,20160119,20160119,EXP,,CH-CIPLA LTD.-2016CH00227,CIPLA,"AOURI M, BARCELO C, TERNON B, CAVASSINI M, ANAGNOSTOPOULOS A, DECOSTERD L ET AL. IN VIVO PROFILING AND DISTRIBUTION OF KNOWN AND NOVEL PHASE I AND PHASE II METABOLITES OF EFAVIRENZ IN PLASMA, URINE, AND CEREBROSPINAL FLUID. DRUG METABOLISM AND DISPOSITION. 2016?44:151-161",,,,,Y,,,20160119,,OT,CH,CH,Efavirenz,Neurotoxicity,119263391,OT,,,,,,,,,,,
11926357,119263571,1,I,,20160112,20160119,20160119,EXP,,CH-CIPLA LTD.-2016CH00229,CIPLA,"AOURI M, BARCELO C, TERNON B, CAVASSINI M, ANAGNOSTOPOULOS A, DECOSTERD L ET AL. IN VIVO PROFILING AND DISTRIBUTION OF KNOWN AND NOVEL PHASE I AND PHASE II METABOLITES OF EFAVIRENZ IN PLASMA, URINE, AND CEREBROSPINAL FLUID. DRUG METABOLISM AND DISPOSITION. 2016?44:151-161",,,,,Y,,,20160119,,OT,CH,CH,Tenofovir/Emtricitabine/Efavirenz,Drug level increased;Neurotoxicity,119263571,OT,,,,,,,,,119263571,1,HIV test positive
11926358,119263581,1,I,,20160112,20160119,20160119,EXP,,CH-CIPLA LTD.-2016CH00228,CIPLA,"AOURI M, BARCELO C, TERNON B, CAVASSINI M, ANAGNOSTOPOULOS A, DECOSTERD L ET AL. IN VIVO PROFILING AND DISTRIBUTION OF KNOWN AND NOVEL PHASE I AND PHASE II METABOLITES OF EFAVIRENZ IN PLASMA, URINE, AND CEREBROSPINAL FLUID. DRUG METABOLISM AND DISPOSITION. 2016?44:151-161",,,,,Y,,,20160119,,OT,CH,CH,Efavirenz,Neurotoxicity,119263581,OT,,,,,,,,,119263581,1,HIV infection
11929354,119293541,1,I,,20160112,20160120,20160120,EXP,,CH-CIPLA LTD.-2016CH00226,CIPLA,"AOURI M, BARCELO C, TERNON B, CAVASSINI M, ANAGNOSTOPOULOS A, DECOSTERD L ET AL. IN VIVO PROFILING AND DISTRIBUTION OF KNOWN AND NOVEL PHASE I AND PHASE II METABOLITES OF EFAVIRENZ IN PLASMA, URINE, AND CEREBROSPINAL FLUID. DRUG METABOLISM AND DISPOSITION. 2016?44:151-161",,,,,Y,,,20160120,,OT,CH,CH,Efavirenz,Neurotoxicity,119293541,OT,,,,,,,,,,,
11929441,119294411,1,I,,20160113,20160120,20160120,EXP,,US-ASPEN PHARMA TRADING LIMITED US-AG-2016-000179,ASPEN,"JOHNSTON C, HARRINGTON R, JAIN R. SAFETY AND EFFICACY OF COMBINATION ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUSEINFECTED ADULTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES. BIOL BLOOD MARROW TRANSPLANT. 2016?22:149-156.",32,YR,,F,Y,,,20160120,,OT,US,US,EFAVIRENZ,Bronchopulmonary aspergillosis;Cytomegalovirus infection;Off label use,119294411,OT,,,,,,,,,119294411,1,Bone marrow conditioning regimen
11930792,119307921,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193343,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119307921,OT,,,,,,,,,119307921,1,HIV infection
11931014,119310141,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193342,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119310141,OT,,,,,,,,,119310141,1,HIV infection
11932477,119324771,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193586,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119324771,OT,,,,,,,,,119324771,1,HIV infection
11932540,119325401,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193588,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119325401,OT,,,,,,,,,119325401,1,HIV infection
11932603,119326031,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193590,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119326031,OT,,,,,,,,,119326031,1,HIV infection
11932693,119326931,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193592,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119326931,OT,,,,,,,,,119326931,1,HIV infection
11932702,119327021,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193306,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327021,OT,,,,,,,,,119327021,1,HIV infection
11932708,119327081,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193589,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327081,OT,,,,,,,,,119327081,1,HIV infection
11932739,119327391,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193587,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327391,OT,,,,,,,,,119327391,1,HIV infection
11932775,119327751,1,I,,20160112,20160120,20160120,EXP,,CN-GILEAD-2016-0193591,GILEAD,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI?S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160120,,MD,CN,CN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119327751,OT,,,,,,,,,119327751,1,HIV infection
11935840,119358401,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007662,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358401,OT,,,,,,,,,119358401,1,HIV infection
11935842,119358421,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007657,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358421,OT,,,,,,,,,119358421,1,HIV infection
11935843,119358431,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007661,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358431,OT,,,,,,,,,119358431,1,HIV infection
11935844,119358441,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007603,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358441,OT,,,,,,,,,119358441,1,HIV infection
11935845,119358451,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007654,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358451,OT,,,,,,,,,119358451,1,HIV infection
11935846,119358461,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007642,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358461,OT,,,,,,,,,119358461,1,HIV infection
11935847,119358471,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007644,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358471,OT,,,,,,,,,119358471,1,HIV infection
11935848,119358481,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007651,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358481,OT,,,,,,,,,119358481,1,HIV infection
11935849,119358491,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007656,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358491,OT,,,,,,,,,119358491,1,HIV infection
11935850,119358501,1,I,,20160112,20160121,20160121,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016007600,VIIV,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119358501,OT,,,,,,,,,119358501,1,HIV infection
11936411,119364111,1,I,,20160111,20160121,20160121,EXP,,CN-GILEAD-2016-0192361,GILEAD,"LIU, X., WU, H., HUANG, X.. DISSEMINATED PENICILLIUM MARNEFFEI INFECTION WITH IRIS. IDCASES. 2015?2(4):92-93",47,YR,A,M,Y,,,20160121,,OT,CN,CN,EFAVIRENZ,Acute kidney injury;Fungal infection;Immune reconstitution inflammatory syndrome,119364111,OT,,,,,,,,,119364111,1,HIV infection
11937013,119370131,1,I,,20160114,20160121,20160121,EXP,,CA-ABBVIE-16P-028-1539955-00,ABBVIE,,84,YR,,M,Y,,,20160121,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,119370131,OT,,,,,,,,,119370131,1,Product used for unknown indication
11937333,119373331,1,I,2015,20160113,20160121,20160121,EXP,,US-GILEAD-2016-0193635,GILEAD,,49,YR,A,M,Y,,,20160121,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Wrist fracture,119373331,OT,,,,,,,,,119373331,1,HIV infection
11937618,119376182,2,F,,20160228,20160122,20160303,EXP,,CA-009507513-1601CAN007640,MERCK,,,,,M,Y,,,20160303,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,119376182,OT,,,,,,,,,119376182,1,Product used for unknown indication
11938845,119388451,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007654,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388451,OT,,,,,,,,,119388451,1,HIV infection
11938846,119388461,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007642,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388461,OT,,,,,,,,,119388461,1,HIV infection
11938851,119388511,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007644,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388511,OT,,,,,,,,,119388511,1,HIV infection
11938855,119388551,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007662,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388551,OT,,,,,,,,,119388551,1,HIV infection
11938859,119388591,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007603,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388591,OT,,,,,,,,,119388591,1,HIV infection
11938863,119388631,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007651,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388631,OT,,,,,,,,,119388631,1,HIV infection
11938867,119388671,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007600,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388671,OT,,,,,,,,,119388671,1,HIV infection
11938875,119388751,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007656,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388751,OT,,,,,,,,,119388751,1,HIV infection
11938878,119388781,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007661,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388781,OT,,,,,,,,,119388781,1,HIV infection
11938879,119388791,1,I,,20160112,20160122,20160122,EXP,,CN-GLAXOSMITHKLINE-CN2016007657,GLAXOSMITHKLINE,"YANG, T., HE, L., WAN, X., MAIMAITIAILI, W., SONG, Y., ZANG, Y., LU, X.. THE CLINICAL CHARACTERISTICS OF 80 CASES OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED KAPOSI^S SARCOMA IN XINJIANG AUTONOMOUS REGION AND THE EFFECT OF DIFFERENT TREATMENTS ON THE PROGNOSIS. INT J CLIN EXP MED 2015. 2015?8(10):18697-18704",,,A,,Y,,,20160121,,MD,CN,CN,Efavirenz,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,119388791,OT,,,,,,,,,119388791,1,HIV infection
11940055,119400555,5,F,20160112,20160125,20160122,20160128,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-003072,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,73.6,KG,20160128,,OT,ZW,ZW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Sepsis,119400555,OT,,,119400555,1,20150818,20151208,,,119400555,1,Kaposi's sarcoma AIDS related
11948410,119484101,1,I,201511,20160112,20160125,20160125,EXP,MA20152691,FR-MYLANLABS-2016M1002641,MYLAN,,,,,,Y,,,20160125,,OT,FR,FR,EFAVIRENZ MYLAN 600 MG COMPRIM?S PELLICUL?S,Condition aggravated;Gamma-glutamyltransferase increased;Nightmare;Product substitution issue,119484101,OT,,,119484101,1,2015,20151116,,,119484101,1,Product used for unknown indication
11952464,119524641,1,I,20160115,20160118,20160125,20160125,EXP,,US-GILEAD-2016-0193991,GILEAD,,50,YR,A,F,Y,,,20160125,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cough;Dyspnoea;Pneumocystis jirovecii pneumonia,119524641,HO,,,,,,,,,119524641,1,HIV infection
11953570,119535701,1,I,,20151216,20160125,20160125,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-092882,BRISTOL MYERS SQUIBB,,15,MON,,M,Y,3.3,KG,20160125,,OT,PT,PT,EFAVIRENZ,Foetal exposure during pregnancy;Psychomotor skills impaired,119535701,OT,,,119535701,1,2007,,,,119535701,1,Product used for unknown indication
11964515,119645151,1,I,,20160115,20160127,20160127,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-003862,BRISTOL MYERS SQUIBB,,,,,M,Y,86.8,KG,20160127,,CN,US,US,SUSTIVA,Incorrect product storage,,,,,119645151,1,1999,,,,119645151,1,HIV infection
11966476,119664761,1,I,,20160119,20160127,20160127,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004404,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160127,,CN,US,US,SUSTIVA,Adverse event,,,,,119664761,1,2013,,,,119664761,1,Product used for unknown indication
11967531,119675314,4,F,20160112,20160201,20160127,20160205,EXP,,ZW-GILEAD-2016-0193802,GILEAD,,39,YR,A,F,Y,73.6,KG,20160205,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Sepsis,119675314,HO,,,119675314,1,20150818,20160117,,,119675314,1,HIV infection
11968401,119684011,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00520,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL  RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128,,OT,GB,GB,Efavirenz,Myocardial ischaemia,119684011,OT,,,,,,,,,119684011,1,HIV infection
11969057,119690571,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00486,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128,,OT,GB,GB,Efavirenz,Hepatitis A;Lactic acidosis;Treatment failure,119690571,OT,,,,,,,,,119690571,1,HIV infection
11969070,119690701,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00487,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128,,OT,GB,GB,Efavirenz,Nervous system disorder;Treatment failure,119690701,DE,,,,,,,,,119690701,1,HIV infection
11969134,119691341,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00488,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING  ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-98",,,,,Y,,,20160128,,OT,COUNTRY NOT SPECIFIED,GB,Efavirenz,Encephalopathy;Treatment failure,119691341,DE,,,,,,,,,119691341,1,HIV infection
11969345,119693451,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00522,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL  RANDOMISED TRIAL. LANCET. 2006?368:287-98",,,,,Y,,,20160128,,OT,GB,GB,Efavirenz,Lactic acidosis,119693451,OT,,,,,,,,,119693451,1,HIV infection
11969396,119693961,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00527,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING  ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128,,OT,GB,GB,Efavirenz,Myocardial infarction;Treatment failure,119693961,OT,,,,,,,,,119693961,1,HIV infection
11969411,119694111,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00528,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING  ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE  TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160128,,OT,GB,GB,Efavirenz,Atypical mycobacterial infection;Treatment failure,119694111,DE,,,,,,,,,119694111,1,HIV infection
11969474,119694741,1,I,,20160117,20160128,20160128,EXP,,GB-CIPLA LTD.-2016GB00529,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE  REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-98",,,,,Y,,,20160128,,OT,GB,GB,Efavirenz,Cytomegalovirus infection;Treatment failure,119694741,OT,,,,,,,,,119694741,1,HIV infection
11969910,119699102,2,F,20151130,20160129,20160128,20160130,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004607,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,61.5,KG,20160130,,OT,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Acute respiratory distress syndrome;Pyrexia,119699102,OT,,,119699102,1,20150408,20150501,,,119699102,1,Acquired immunodeficiency syndrome
11971701,119717011,1,I,,20160120,20160128,20160128,EXP,,US-BMSGILMSD-2016-0194540,GILEAD,,63,YR,A,F,Y,,,20160128,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypertension;Nervousness,119717011,OT,,,,,,,,,119717011,1,HIV infection
11972261,119722611,1,I,,20160116,20160128,20160128,EXP,,IN-MYLANLABS-2016M1003489,MYLAN,"KARADE S, PANDEY S, GIANCHANDANI S, KURLE SN, GHATE M, GAIKWAD NS, ET AL. NEAR FULL-LENGTH GENOMIC CHARACTERIZATION OF A NOVEL CRF 01-AE/C RECOMBINANT FROM WESTERN INDIA. AIDS-RES-HUM-RETROVIRUSES 2015?31(12):1269-1273.",,,,,Y,,,20160128,,OT,IN,IN,EFAVIRENZ,Drug resistance;Treatment failure,119722611,OT,,,,,,,,,119722611,1,Antiretroviral therapy
11972859,119728593,3,F,20160112,20160216,20160128,20160226,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-003234,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,1.96,KG,20160226,,MD,BR,BR,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,119728593,OT,,,119728593,1,20151113,20160111,,,119728593,1,Product used for unknown indication
11976292,119762921,1,I,,20160117,20160129,20160129,EXP,,GB-CIPLA LTD.-2016GB00489,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160129,,OT,GB,GB,Efavirenz,Pulmonary hypertension;Treatment failure,119762921,DE,,,,,,,,,119762921,1,HIV infection
11981281,119812811,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00498,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Pyrexia,119812811,DE,,,,,,,,,119812811,1,HIV infection
11981282,119812821,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00499,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Oedema;Treatment failure,119812821,OT,,,,,,,,,119812821,1,HIV infection
11981283,119812831,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00500,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Death;Treatment failure,119812831,OT,,,,,,,,,119812831,1,HIV infection
11981284,119812841,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00501,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Death;Treatment failure,119812841,DE,,,,,,,,,119812841,1,HIV infection
11981285,119812851,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00503,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Myocardial infarction;Treatment failure,119812851,OT,,,,,,,,,119812851,1,HIV infection
11981286,119812861,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00505,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Angina pectoris;Myocardial ischaemia;Treatment failure,119812861,OT,,,,,,,,,119812861,1,HIV infection
11981287,119812871,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00502,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,CN,GB,GB,Efavirenz,Lactic acidosis;Treatment failure,119812871,OT,,,,,,,,,119812871,1,HIV infection
11981288,119812881,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00504,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Blood cholesterol increased;Blood triglycerides increased;Treatment failure,119812881,OT,,,,,,,,,119812881,1,HIV infection
11981289,119812891,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00506,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,CN,GB,GB,Efavirenz,Blood bilirubin increased;Treatment failure,119812891,OT,,,,,,,,,119812891,1,HIV infection
11981290,119812901,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00508,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Amylase increased;Treatment failure,119812901,OT,,,,,,,,,119812901,1,HIV infection
11981291,119812911,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00510,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Oedema;Treatment failure,119812911,OT,,,,,,,,,119812911,1,HIV infection
11981292,119812921,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00511,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Blood bilirubin increased,119812921,OT,,,,,,,,,119812921,1,HIV infection
11981293,119812931,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00509,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Cardiac failure;Pulmonary oedema;Shock;Treatment failure,119812931,OT,,,,,,,,,119812931,1,HIV infection
11981294,119812941,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00507,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Pancreatitis;Treatment failure,119812941,OT,,,,,,,,,119812941,1,HIV infection
11981295,119812951,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00515,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Respiratory disorder;Treatment failure,119812951,OT,,,,,,,,,119812951,1,HIV infection
11981300,119813001,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00516,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Myocardial infarction,119813001,OT,,,,,,,,,119813001,1,HIV infection
11981306,119813061,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00513,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Genitourinary symptom;Renal disorder,119813061,OT,,,,,,,,,119813061,1,HIV infection
11981307,119813071,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00514,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Lactic acidosis;Treatment failure,119813071,OT,,,,,,,,,119813071,1,HIV infection
11981308,119813081,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00512,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Lactic acidosis,119813081,OT,,,,,,,,,119813081,1,HIV infection
11981309,119813091,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00519,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Myocardial infarction;Treatment failure,119813091,OT,,,,,,,,,119813091,1,HIV infection
11981310,119813101,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00517,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Oedema,119813101,OT,,,,,,,,,119813101,1,HIV infection
11981311,119813111,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00518,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Hyperlactacidaemia;Treatment failure,119813111,OT,,,,,,,,,119813111,1,HIV infection
11981312,119813121,1,I,,20160117,20160130,20160130,EXP,,GB-CIPLA LTD.-2016GB00521,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160130,,OT,GB,GB,Efavirenz,Oedema,119813121,OT,,,,,,,,,119813121,1,HIV infection
11981807,119818071,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00540,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Pneumocystis jirovecii pneumonia;Treatment failure,119818071,DE,,,,,,,,,119818071,1,HIV infection
11981917,119819171,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00497,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?398:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Homicide,119819171,DE,,,,,,,,,119819171,1,HIV infection
11981926,119819261,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00526,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Myocardial ischaemia;Treatment failure,119819261,OT,,,,,,,,,119819261,1,HIV infection
11981927,119819271,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00525,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Oesophageal candidiasis;Treatment failure,119819271,DE,,,,,,,,,119819271,1,HIV infection
11981929,119819291,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00524,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Cardiac failure;Pulmonary oedema;Shock,119819291,OT,,,,,,,,,119819291,1,HIV infection
11981935,119819351,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00523,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Genitourinary symptom;Renal disorder,119819351,OT,,,,,,,,,119819351,1,HIV infection
11981937,119819371,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00530,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,AIDS dementia complex;Treatment failure,119819371,DE,,,,,,,,,119819371,1,HIV infection
11981940,119819401,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00535,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-296",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,AIDS dementia complex;Treatment failure,119819401,DE,,,,,,,,,119819401,1,HIV infection
11981941,119819411,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00531,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Pneumocystis jirovecii pneumonia;Treatment failure,119819411,OT,,,,,,,,,119819411,1,HIV infection
11981943,119819431,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00532,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Meningitis cryptococcal;Treatment failure,119819431,OT,,,,,,,,,119819431,1,HIV infection
11981948,119819481,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00539,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,AIDS dementia complex,119819481,DE,,,,,,,,,119819481,1,HIV infection
11981949,119819491,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00537,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Progressive multifocal leukoencephalopathy,119819491,DE,,,,,,,,,119819491,1,HIV infection
11981950,119819501,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00536,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Pneumocystis jirovecii pneumonia,119819501,DE,,,,,,,,,119819501,1,HIV infection
11981963,119819631,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00538,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Meningitis cryptococcal,119819631,DE,,,,,,,,,119819631,1,HIV infection
11981967,119819671,1,I,,20160117,20160201,20160201,EXP,,GB-CIPLA LTD.-2016GB00541,CIPLA,"BABIKER A G, YENI P, COOPER D A , ABOULKER J-P, CAREY D, DARBYSHIRE J H ET AL. VIROLOGICAL AND IMMUNOLOGICAL OUTCOMES AT 3 YEARS AFTER STARTING ANTIRETROVIRAL THERAPY WITH REGIMENS CONTAINING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, PROTEASE INHIBITOR, OR BOTH IN INITIO: OPEN-LABEL RANDOMISED TRIAL. LANCET. 2006?368:287-298",,,,,Y,,,20160201,,OT,GB,GB,Efavirenz,Cryptosporidiosis infection,119819671,DE,,,,,,,,,119819671,1,HIV infection
11986322,119863221,1,I,20141204,20160127,20160202,20160202,EXP,,FR-ROCHE-1702329,ROCHE,,67,YR,,M,Y,,,20160202,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Acute kidney injury,119863221,HO,,,119863221,1,20141201,20141204,,,119863221,1,Influenza
11991033,119910332,2,F,,20160228,20160202,20160228,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160228,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,119910332,OT,,,,,,,,,119910332,1,Product used for unknown indication
11993203,119932032,2,F,,20160122,20160203,20160204,EXP,,CA-TEVA-630951ACC,TEVA,,65,YR,,M,Y,,,20160204,,MD,CA,CA,SUSTIVA,Palpitations;Product substitution issue,119932032,DS,,,,,,,,,119932032,1,HIV test positive
11996013,119960132,2,F,20160106,20160226,20160203,20160303,EXP,,BR-GILEAD-2016-0194835,GILEAD,,28,YR,A,M,Y,60,KG,20160303,,MD,BR,BR,EFAVIRENZ,Nephrolithiasis,119960132,HO,,,119960132,1,20130507,,,,119960132,1,HIV infection
12000812,120008121,1,I,,20160126,20160204,20160204,EXP,,KR-JNJFOC-20160120632,JANSSEN,"KIM MJ, KIM S, CHANG H, KIM Y, JIN S, JUNG H, ET AL. COMPARISON OF ANTIRETROVIRAL REGIMENS: ADVERSE EFFECTS AND TOLERABILITY FAILURE THAT CAUSE REGIMEN SWITCHING. INFECT CHEMOTHER 2015?47(4):231-238.",,,A,,Y,,,20160204,,OT,KR,KR,EFAVIRENZ,Abdominal pain upper;Alanine aminotransferase increased;Aspartate aminotransferase increased;Diabetes mellitus;Diarrhoea;Dizziness;Headache;Hyperbilirubinaemia;Nausea;Pain in extremity;Rash,120008121,OT,,,,,,,,,120008121,1,HIV infection
12001258,120012581,1,I,,20160129,20160204,20160204,EXP,,US-BMSGILMSD-2016-0196168,GILEAD,,46,YR,A,M,Y,,,20160204,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip surgery,120012581,OT,,,,,,,,,120012581,1,HIV infection
12001270,120012701,1,I,,20160129,20160204,20160204,EXP,,US-GILEAD-2016-0195944,GILEAD,,54,YR,A,M,Y,,,20160204,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure congestive;Chronic kidney disease;Hyperlipidaemia;Type 2 diabetes mellitus,120012701,OT,,,,,,,,,120012701,1,HIV infection
12005836,120058361,1,I,,20160202,20160205,20160205,EXP,,US-GILEAD-2016-0196236,GILEAD,,54,YR,A,F,Y,,,20160204,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain injury;Physical assault,120058361,HO,,,,,,,,,120058361,1,HIV infection
12007426,120074261,1,I,,20160112,20160204,20160204,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-002427,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160204,,LW,US,US,SUSTIVA,Mass;Nervous system disorder,,,,,,,,,,,120074261,1,Product used for unknown indication
12009821,120098211,1,I,,20160122,20160205,20160205,EXP,,IN-LUPIN PHARMACEUTICALS INC.-2016-00532,LUPIN,"GANGAKHEDKAR R, KARADE S, PANDEY S, GIANCHANDANI S, KURLE S, GHATE M, GAIKWAD N, REWARI B. NEAR FULL-LENGTH GENOMIC CHARACTERIZATION OF A NOVEL CRF 01_AE/C RECOMBINANT FROM WESTERN INDIA. AIDS-RES-HUM-RETROVIRUSES. 2015?31(12):1269-1273.",32,YR,,F,Y,,,20160205,,OT,IN,IN,EEFAVIRENZ,Drug resistance;Treatment failure,120098211,OT,,,,,,,,,120098211,1,HIV infection
12013178,120131782,2,F,,20160314,20160205,20160323,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-005611,BRISTOL MYERS SQUIBB,,66,YR,,F,Y,,,20160323,,PH,DE,DE,SUSTIVA,Dysphagia;Gastrointestinal tube insertion;Tumour excision,120131782,OT,,,,,,,,,120131782,1,HIV infection
12036755,120367551,1,I,2012,20120511,20160208,20160208,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-16593147,BRISTOL MYERS SQUIBB,,,,,M,Y,94,KG,20160208,,CN,GB,GB,EFAVIRENZ,Head discomfort;Jaundice;Off label use;Sleep disorder,120367551,OT,,,120367551,1,20120327,20120510,,,120367551,1,Immunosuppression
12052728,120527281,1,I,20160130,20160201,20160209,20160209,EXP,,US-GLAXOSMITHKLINE-US2016014439,GLAXOSMITHKLINE,,,,A,M,Y,,,20160209,,CN,US,US,SUSTIVA,Insomnia;Nightmare;Somnolence,,,,,120527281,2,20160130,,,,120527281,1,Product used for unknown indication
12054283,120542831,1,I,20160130,20160201,20160209,20160209,EXP,,US-VIIV HEALTHCARE LIMITED-US2016014439,VIIV,,,,A,M,Y,,,20160209,,CN,US,US,SUSTIVA,Insomnia;Nightmare;Somnolence,,,,,120542831,2,20160130,,,,120542831,1,Product used for unknown indication
12061046,120610461,1,I,2014,20160203,20160210,20160210,EXP,,US-GILEAD-2016-0196907,GILEAD,,61,YR,A,M,Y,,,20160210,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Cerebrovascular accident;Encephalopathy;HIV infection;Memory impairment;Neoplasm malignant;Treatment noncompliance,120610461,OT,,,,,,,,,120610461,1,HIV infection
12062313,120623131,1,I,,20160202,20160210,20160210,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2016GSK016070,VIIV,,48,YR,,M,Y,,,20160210,,MD,FR,FR,EFAVIRENZ,Mitochondrial toxicity,120623131,OT,,,,,,,,,120623131,1,HIV infection
12070744,120707441,1,I,20151221,20160208,20160211,20160211,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK018366,VIIV,,49,YR,,M,Y,,,20160211,,CN,GB,GB,Efavirenz,Ankle fracture;Surgery,120707441,HO,,,,,,,,,120707441,1,Product used for unknown indication
12070761,120707611,1,I,20151221,20160208,20160211,20160211,EXP,,GB-GLAXOSMITHKLINE-GB2016GSK018366,GLAXOSMITHKLINE,,49,YR,,M,Y,,,20160211,,CN,GB,GB,Efavirenz,Ankle fracture;Surgery,120707611,HO,,,,,,,,,120707611,1,Product used for unknown indication
12070911,120709111,1,I,20150928,20151001,20160211,20160211,EXP,,KE-GILEAD-2015-0175436,GILEAD,,27,YR,A,F,Y,46.2,KG,20160211,,MD,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Ascites;Pleural effusion,120709111,HO,,,120709111,1,20150917,20151209,,,120709111,1,Kaposi's sarcoma AIDS related
12070929,120709291,1,I,,20151214,20160211,20160211,EXP,,GB-GILEAD-2015-0189409,GILEAD,,,,,M,Y,,,20160211,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Intentional product misuse,120709291,OT,,,,,,,,,120709291,1,HIV infection
12071121,120711211,1,I,20160128,20160202,20160211,20160211,EXP,,MW-GILEAD-2016-0197007,GILEAD,,33,YR,A,M,Y,,,20160211,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaria,120711211,HO,,,120711211,1,20150824,20160127,,,120711211,1,HIV infection
12071257,120712571,1,I,20151102,20160204,20160211,20160211,EXP,,GB-GILEAD-2016-0196945,GILEAD,,64,YR,,M,Y,64,KG,20160211,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Feeding disorder;Gastrooesophageal reflux disease;Infection;Malaise;Oropharyngeal pain,120712571,HO,,,120712571,1,20090205,20160122,,,120712571,1,HIV infection
12073158,120731581,1,I,,20160129,20160212,20160212,EXP,,RS-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-111401,RANBAXY,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC D. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: CASE REPORT. INT-J-INFECT-DIS. 2016?4240-42",28,YR,,M,Y,,,20160212,,OT,RS,RS,Efavirenz,Condition aggravated;Drug resistance;Immune reconstitution inflammatory syndrome,120731581,OT,,,,,,,,,120731581,1,Antiretroviral therapy
12074101,120741011,1,I,,20160202,20160212,20160212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-009817,BRISTOL MYERS SQUIBB,MYCOBACTERIUM HAEMNOPHILUM BONE AND JOINT INFECTION IN HIV/AIDS: CASE REPORT AND LITERATURE REVIEW,60,YR,,M,Y,,,20160212,,MD,AU,AU,EFAVIRENZ,Debridement;Haemophilus infection;Immune reconstitution inflammatory syndrome,120741011,OT,,,,,,,,,120741011,1,Antiretroviral therapy
12081585,120815851,1,I,,20160205,20160216,20160216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-012079,BRISTOL MYERS SQUIBB,,72,YR,,M,Y,,,20160216,,OT,US,US,EFAVIRENZ,Drug intolerance,,,,,,,,,,,120815851,1,HIV infection
12090160,120901601,1,I,,20160205,20160218,20160218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-011281,BRISTOL MYERS SQUIBB,,46,YR,,F,Y,,,20160218,,OT,US,US,EFAVIRENZ,Fanconi syndrome,120901601,OT,,,,,,,,,120901601,1,HIV infection
12090219,120902191,1,I,,20160205,20160218,20160218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-012078,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20160218,,OT,US,US,EFAVIRENZ,Anxiety;Depression,120902191,OT,,,,,,,,,120902191,1,HIV infection
12091740,120917401,1,I,,20160211,20160218,20160218,EXP,,US-BMSGILMSD-2016-0198859,GILEAD,,49,YR,A,M,Y,,,20160218,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Decreased appetite;Diabetes mellitus;Nasal ulcer;Pyrexia;Vision blurred,120917401,OT,,,,,,,,,120917401,1,HIV infection
12093825,120938251,1,I,,20160209,20160219,20160219,EXP,,ES-GLAXOSMITHKLINE-ES2016GSK022612,GLAXOSMITHKLINE,"FERNANDEZ-ALVAREZ R, GONZALEZ-RODRIGUEZ AP, RUBIO-CASTRO A, GONZALEZ ME, PAYER AR, ALONSO-GARCIA A ET AL. BORTEZOMIB PLUS CHOP FOR THE TREATMENT OF HIV ASSOCIATED PLASMABLASTIC LYMPHOMA: CLINICAL EXPERIENCE IN THREE PATIENTS. LEUKEMIA + LYMPHOMA. 2016?57 (2):463-466",39,YR,,M,Y,,,20160219,,OT,ES,ES,Efavirenz,Anaemia;Neutropenia;Peripheral sensorimotor neuropathy;Sepsis;Thrombocytopenia,120938251,OT,,,,,,,,,120938251,1,Plasmablastic lymphoma
12094221,120942211,1,I,,20160211,20160219,20160219,EXP,,PHHY2016ES020236,SANDOZ,"FERNANDEZ-ALVAREZ R, GONZALEZ-RODRIGUEZ AP, RUBIO-CASTRO A, GONZALEZ ME, PAYER AR, ALONSO-GARCIA. BORTEZOMIB PLUS CHOP FOR THE TREATMENT OF HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA: CLINICAL EXPERIENCE IN THREE PATIENTS. LEUK-LYMPHOMA. 2016?57(2):463-6",39,YR,,M,Y,,,20160219,,OT,ES,ES,EFAVIRENZ,Anaemia;Cytomegalovirus chorioretinitis;Neuropathy peripheral;Neutropenia;Progressive multifocal leukoencephalopathy;Sepsis;Thrombocytopenia;Viral haemorrhagic cystitis,120942211,OT,,,,,,,,,120942211,1,Plasmablastic lymphoma
12094517,120945171,1,I,20150506,20160202,20160219,20160219,EXP,,GB-GILEAD-2016-0196404,GILEAD,,68,YR,E,M,Y,60,KG,20160219,,OT,GB,GB,EFAVIRENZ,Anaemia,120945171,HO,,,120945171,1,20150408,20150701,,,120945171,1,Hepatitis C
12095787,120957871,1,I,,20160208,20160220,20160220,EXP,,ES-CIPLA LTD.-2016ES01159,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160220,,OT,ES,ES,Efavirenz,Blood bilirubin increased,120957871,OT,,,,,,,,,120957871,1,HIV infection
12095793,120957931,1,I,,20160208,20160220,20160220,EXP,,ES-CIPLA LTD.-2016ES01161,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160220,,OT,ES,ES,Efavirenz,Blood bilirubin increased,120957931,OT,,,,,,,,,120957931,1,HIV infection
12095794,120957941,1,I,,20160208,20160220,20160220,EXP,,ES-CIPLA LTD.-2016ES01160,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160220,,OT,ES,ES,Efavirenz,Blood bilirubin increased,120957941,OT,,,,,,,,,120957941,1,HIV infection
12098641,120986411,1,I,,20160208,20160222,20160222,EXP,,US-CIPLA LTD.-2016US01275,CIPLA,"BARIL J, ANGEL JB, GILL MJ, GATHE J, CAHN P, WYK J AND WALMSLEY S. DUAL THERAPY TREATMENT STRATEGIES FOR THE MANAGEMENT OF PATIENTS INFECTED WITH HIV: A SYSTEMATIC REVIEW OF CURRENT EVIDENCE IN ARV-NAIVE OR ARV-EXPERIENCED, VIROLOGICALLY SUPPRESSED PATIENTS. PLUS ONE. 2016?11 (2):1-32",,,,,Y,,,20160222,,OT,CA,US,Efavirenz,Suicidal ideation,120986411,OT,,,,,,,,,120986411,1,HIV infection
12099310,120993101,1,I,,20160208,20160222,20160222,EXP,,ES-CIPLA LTD.-2016ES01168,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160222,,OT,ES,ES,Efavirenz,Encephalopathy;Haemorrhage,120993101,DE,,,,,,,,,120993101,1,HIV infection
12099433,120994331,1,I,,20160208,20160222,20160222,EXP,,ES-CIPLA LTD.-2016ES01169,CIPLA,"NEUKAM K, MIRA J, COLLADO A, RIVERO-JUAREZ A, MONJE-AGUDO P, RUIZ-MORALES J, ET AL.. LIVER TOXICITY OF CURRENT ANTIRETROVIRAL REGIMENS IN HIV-INFECTED PATIENTS WITH CHRONIC VIRAL HEPATITIS IN A REAL-LIFE SETTING: THE HEPAVIR SEG-HEP COHORT. PLOS ONE. 2016?1-12",,,,,Y,,,20160222,,OT,ES,ES,Efavirenz,Virologic failure,120994331,OT,,,,,,,,,120994331,1,HIV infection
12099496,120994961,1,I,,20160208,20160222,20160222,EXP,,US-CIPLA LTD.-2016US01277,CIPLA,"BARIL J, ANGEL JB, GILL MJ, GATHE J, CAHN P, WYK J AND WALMSLEY S. DUAL THERAPY TREATMENT STRATEGIES FOR THE MANAGEMENT OF PATIENTS INFECTED WITH HIV: A SYSTEMATIC REVIEW OF CURRENT EVIDENCE IN ARV-NAIVE OR ARV-EXPERIENCED, VIROLOGICALLY SUPPRESSED PATIENTS. PLOS ONE. 2016?11(2):1-32",,,,,Y,,,20160222,,OT,CA,US,Tenofovir/Emtricitabine/Efavirenz,Adverse event,120994961,OT,,,,,,,,,120994961,1,HIV infection
12099778,120997781,1,I,2013,20160212,20160222,20160222,EXP,,US-BMSGILMSD-2016-0198941,GILEAD,,66,YR,E,M,Y,,,20160222,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,120997781,HO,,,,,,,,,120997781,1,HIV infection
12100419,121004191,1,I,,20160106,20160222,20160222,PER,,US-JNJFOC-20160109857,JANSSEN,"DOOLEY KE, PARK J, SWINDELLS S, ALLEN R, HAAS DW, CRAMER Y, ET AL. SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF THE ANTITUBERCULOUS AGENT TMC207 (BEDAQUILINE) WITH EFAVIRENZ IN HEALTHY VOLUNTEERS: AIDS CLINICAL TRIALS GROUP STUDY A5267 . JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 15-APR-2012?59(5):455-462.",,,A,,Y,,,20160222,,MD,US,US,EFAVIRENZ,Drug interaction;Drug level decreased;Electrocardiogram QT prolonged,121004191,OT,,,,,,,,,121004191,1,Product used for unknown indication
12100420,121004201,1,I,,20160106,20160222,20160222,PER,,US-JNJFOC-20160109858,JANSSEN,"DOOLEY KE, PARK J, SWINDELLS S, ALLEN R, HAAS DW, CRAMER Y, ET AL. SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF THE ANTITUBERCULOUS AGENT TMC207 (BEDAQUILINE) WITH EFAVIRENZ IN HEALTHY VOLUNTEERS: AIDS CLINICAL TRIALS GROUP STUDY A5267. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 15-APR-2012?59(5):455-462.",,,A,,Y,,,20160222,,MD,US,US,EFAVIRENZ,Drug interaction;Drug level decreased;Electrocardiogram QT prolonged,121004201,OT,,,,,,,,,121004201,1,Product used for unknown indication
12100421,121004211,1,I,,20160106,20160222,20160222,PER,,US-JNJFOC-20160109859,JANSSEN,"DOOLEY KE, PARK J, SWINDELLS S, ALLEN R, HAAS DW, CRAMER Y, ET AL. SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF THE ANTITUBERCULOUS AGENT TMC207 (BEDAQUILINE) WITH EFAVIRENZ IN HEALTHY VOLUNTEERS: AIDS CLINICAL TRIALS GROUP STUDY A5267. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 15-APR-2012?59 (5):455?462.",,,A,,Y,,,20160222,,MD,US,US,EFAVIRENZ,Drug interaction;Drug level decreased;Transaminases increased,121004211,OT,,,,,,,,,121004211,1,Product used for unknown indication
12100423,121004231,1,I,,20160106,20160222,20160222,PER,,US-JNJFOC-20160109832,JANSSEN,"DOOLEY KE, PARK J, SWINDELLS S, ALLEN R, HAAS DW, CRAMER Y, ET AL. SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF THE ANTITUBERCULOUS AGENT TMC207 (BEDAQUILINE) WITH EFAVIRENZ IN HEALTHY VOLUNTEERS: AIDS CLINICAL TRIALS GROUP STUDY A5267. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 15-APR-2012?59(5):455-462.",,,,,Y,,,20160222,,MD,US,US,EFAVIRENZ,Treatment noncompliance,,,,,,,,,,,121004231,1,Product used for unknown indication
12100449,121004491,1,I,,20160106,20160222,20160222,PER,,US-JNJFOC-20160121537,JANSSEN,"DOOLEY KE, PARK J, SWINDELLS S, ALLEN R, HAAS DW, CRAMER Y, ET AL. SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF THE ANTITUBERCULOUS AGENT TMC207 (BEDAQUILINE) WITH EFAVIRENZ IN HEALTHY VOLUNTEERS: AIDS CLINICAL TRIALS GROUP STUDY A5267. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 15-APR-2012?59(5):455-462.",,,A,,Y,,,20160222,,MD,US,US,EFAVIRENZ,Transaminases increased,,,,,,,,,,,121004491,1,Product used for unknown indication
12100450,121004501,1,I,,20160106,20160222,20160222,PER,,US-JNJFOC-20160121538,JANSSEN,"DOOLEY KE, PARK J, SWINDELLS S, ALLEN R, HAAS DW, CRAMER Y, ET AL. SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF THE ANTITUBERCULOUS AGENT TMC207 (BEDAQUILINE) WITH EFAVIRENZ IN HEALTHY VOLUNTEERS: AIDS CLINICAL TRIALS GROUP STUDY A5267. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 15-APR-2012?59(5):455-462.",,,A,,Y,,,20160222,,MD,US,US,EFAVIRENZ,Blood bilirubin increased,,,,,,,,,,,121004501,1,Product used for unknown indication
12100710,121007101,1,I,,20160211,20160222,20160222,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-011261,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160222,,PH,ES,ES,SUSTIVA,General physical health deterioration,121007101,OT,,,,,,,,,121007101,1,Product used for unknown indication
12101117,121011171,1,I,,20150401,20160222,20160222,EXP,,GB-009507513-1506GBR001330,MERCK,,,,,F,Y,,,20160222,,CN,US,GB,EFAVIRENZ,Drug resistance;Off label use;Virologic failure,121011171,OT,,,121011171,1,201111,,,,121011171,1,HIV infection
12101742,121017422,2,F,20160125,20160225,20160222,20160302,EXP,,UG-GILEAD-2016-0197817,GILEAD,,22,YR,A,F,Y,,,20160302,,MD,UG,UG,EFAVIRENZ,Abortion infected;Anaemia;Malaria;Maternal exposure during pregnancy,121017422,HO,,,121017422,1,20150401,20160205,,,121017422,1,HIV infection
12105259,121052591,1,I,2012,20120528,20160223,20160223,EXP,,GB-GLAXOSMITHKLINE-B0804044A,GLAXOSMITHKLINE,,43,YR,,M,Y,94,KG,20160223,,CN,GB,GB,Efavirenz,Head discomfort;Jaundice;Off label use;Sleep disorder,121052591,OT,,,121052591,1,2010,20120326,,,121052591,1,Immunosuppression
12105497,121054972,2,F,,20160219,20160223,20160225,EXP,,PHHY2016FR023160,SANDOZ,"LATOUR RP, MARSH J, PAGLIUCA S, GERAD L, KULASEKARARAJ A, EAPEN M ET.AL.,. CHARACTERISTICS AND OUTCOMES OF APLASTIC ANEMIA IN HIV PATIENTS: A BRIEF REPORT FROM THE SEVERE APLASTIC ANEMIA WORKING PARTY OF THE EUROPEAN SOCIETY OF BLOOD AND BONE MARROW TRANSPLANTATION.. BONE MARROW TRANSPLANTATION. 2016?51 (2):313-5",,,A,M,Y,,,20160225,,OT,FR,FR,EFAVIRENZ,Drug ineffective;Neutropenic infection;Product use issue,121054972,DE,,,,,,,,,121054972,1,Aplastic anaemia
12106278,121062781,1,I,,20160209,20160223,20160223,EXP,,CA-WATSON-2016-03350,WATSON,"NEWMAN M, FOISY MM, AHMED RA. THE USE OF THERAPEUTIC DRUG MONITORING IN COMPLEX ANTITUBERCULOUS AND ANTIRETROVIRAL DRUG DOSING IN HIV/TUBERCULOSIS-COINFECTED PATIENTS. J INT ASSOC PROVID AIDS CARE. 2015?14(4):295-9",46,YR,,M,Y,72.5,KG,20160223,,OT,CA,CA,Efavirenz (Unknown),Drug interaction;Drug level above therapeutic;Drug level below therapeutic;Transaminases increased,121062781,OT,,,,,,,,,121062781,1,Pulmonary tuberculosis
12107273,121072732,2,F,20160201,20160217,20160223,20160301,EXP,,US-GILEAD-2016-0199362,GILEAD,,60,YR,A,F,Y,93.6,KG,20160301,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoarthritis,121072732,HO,,,121072732,1,20130222,,,,121072732,1,HIV infection
12111859,121118591,1,I,,20160211,20160224,20160224,EXP,,ES-MYLANLABS-2016M1006941,MYLAN,"FERNANDEZ-ALVAREZ R, GONZALEZ-RODRIGUEZ AP, RUBIO-CASTRO A, GONZALEZ ME, PAYER AR, ALONSO-GARCIA A, ET AL. BORTEZOMIB PLUS CHOP FOR THE TREATMENT OF HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA: CLINICAL EXPERIENCE IN THREE PATIENTS. LEUK-LYMPHOMA 2016?57(2):463-466.",,,,,Y,,,20160224,,OT,ES,ES,EFAVIRENZ,Anaemia;Neutropenia;Peripheral sensory neuropathy;Sepsis;Thrombocytopenia,121118591,OT,,,,,,,,,121118591,1,Plasmablastic lymphoma
12113243,121132431,1,I,,20160211,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01404,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225,,OT,US,US,Efavirenz,Drug resistance;Treatment failure,121132431,OT,,,,,,,,,121132431,1,HIV infection
12113264,121132641,1,I,,20160211,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01412,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225,,OT,US,US,Efavirenz,Road traffic accident,121132641,DE,,,,,,,,,121132641,1,HIV infection
12113286,121132861,1,I,,20160211,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01411,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225,,OT,US,US,Efavirenz,Adenocarcinoma gastric,121132861,DE,,,,,,,,,121132861,1,HIV infection
12113336,121133361,1,I,,20160211,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01391,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225,,OT,US,US,Efavirenz,Sepsis,121133361,DE,,,,,,,,,121133361,1,HIV infection
12114130,121141301,1,I,,20160211,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01444,CIPLA,"FISCHL MA, COLLIER AC, MUKHERJEE AL, FEINBERG JE, DEMETER LM, TEBAS P ET AL.. RANDOMIZED OPEN-LABEL TRIAL OF TWO SIMPLIFIED, CLASS-SPARING REGIMENS FOLLOWING A FIRST SUPPRESSIVE THREE OR FOUR-DRUG REGIMEN. AIDS. 2007?21(3):325 TO 333",,,,,Y,,,20160225,,OT,US,US,Efavirenz,Drowning,121141301,DE,,,,,,,,,121141301,1,HIV infection
12114271,121142711,1,I,,20160211,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01372,CIPLA,"RIDDLER S.A, HAUBRICH R, DIRIENZO G, PEEPLES L, POWDERLY W.G, KLINGMAN K.L., ET AL.. CLASS-SPARING REGIMENS FOR INITIAL TREATMENT OF HIV-1 INFECTION. N ENGL J MED. 2008?358 (20):2095-2106",,,,,Y,,,20160225,,MD,US,US,Efavirenz,Hepatotoxicity,121142711,DE,,,,,,,,,121142711,1,HIV infection
12114276,121142761,1,I,,20160211,20160225,20160225,EXP,,US-CIPLA LTD.-2016US01370,CIPLA,"RIDDLER S.A, HAUBRICH R, DIRIENZO G, PEEPLES L, POWDERLY W.G, KLINGMAN K.L., ET AL.. CLASS-SPARING REGIMENS FOR INITIAL TREATMENT OF HIV-1 INFECTION. N ENGL J MED. 2008?358 (20):2095-2106",,,,,Y,,,20160225,,MD,US,US,Efavirenz,Virologic failure,121142761,OT,,,,,,,,,121142761,1,HIV infection
12114543,121145431,1,I,,20160218,20160225,20160225,EXP,,US-VIIV HEALTHCARE LIMITED-US2016024731,VIIV,,,,,F,Y,,,20160225,,CN,US,US,SUSTIVA,Headache;Malaise,,,,,,,,,,,121145431,1,Product used for unknown indication
12115694,121156941,1,I,,20160218,20160225,20160225,EXP,,US-GLAXOSMITHKLINE-US2016024731,GLAXOSMITHKLINE,,,,,F,Y,,,20160225,,CN,US,US,SUSTIVA,Headache;Malaise,,,,,,,,,,,121156941,1,Product used for unknown indication
12116848,121168482,2,F,20151006,20160308,20160225,20160314,EXP,,ZW-GILEAD-2015-0176985,GILEAD,,51,YR,A,M,Y,69,KG,20160314,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gangrene;Leg amputation;Weight decreased,121168482,HO,,,121168482,1,20150305,20151005,,,121168482,1,Kaposi's sarcoma AIDS related
12118375,121183752,2,F,20150804,20160229,20160226,20160303,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-054403,BRISTOL MYERS SQUIBB,,34,YR,,M,Y,57,KG,20160303,,OT,UG,UG,EFAVIRENZ,Pneumonia;Septic shock,121183752,OT,,,121183752,1,20140321,20150219,,,121183752,1,Tuberculosis
12119616,121196162,2,F,20160118,20160303,20160226,20160308,EXP,,ZW-GILEAD-2016-0194747,GILEAD,,36,YR,A,F,Y,43,KG,20160308,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Gastroenteritis;Hypocalcaemia,121196162,DE,,,121196162,1,20150514,20160117,,,121196162,1,Kaposi's sarcoma AIDS related
12119854,121198542,2,F,20150726,20160310,20160226,20160318,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-014171,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,72,KG,20160318,,CN,CN,CN,EFAVIRENZ,Drug eruption,121198542,OT,,,121198542,1,20150704,20150728,,,121198542,1,Acquired immunodeficiency syndrome
12123126,121231261,1,I,,20160119,20160227,20160227,EXP,,ZA-AUROBINDO-AUR-APL-2016-00768,AUROBINDO,,29,YR,,M,Y,,,20160226,,OT,ZA,ZA,Efavirenz,Hepatitis B;Hepatomegaly;Immune reconstitution inflammatory syndrome;Jaundice;Lymphadenopathy;Pancytopenia;Splenomegaly,121231261,HO,,,121231261,4,200901,,,,121231261,1,HIV infection
12123559,121235591,1,I,20160110,,20160226,20160226,DIR,,,,,56,YR,,M,N,,,20160224,N,,US,,EFAVIRENZ;SUSTIVA,Rash,121235591,OT,,,121235591,1,20160110,20160118,,,121235591,1,HIV infection
12124406,121244061,1,I,2012,20160215,20160229,20160229,EXP,,GB-MYLANLABS-2016M1007193,MYLAN,,43,YR,,M,Y,94,KG,20160229,,CN,GB,GB,EFAVIRENZ,Head discomfort;Jaundice;Off label use;Sleep disorder,121244061,OT,,,121244061,1,20120327,20120326,,,121244061,1,Product used for unknown indication
12125289,121252892,2,F,20130704,20151109,20160229,20160229,PER,,US-ABBVIE-15P-163-1422672-00,ABBVIE,,47,YR,,M,Y,98,KG,20160229,,LW,US,US,SUSTIVA,Thrombosis,121252892,OT,,,121252892,1,20111118,201306,,,121252892,1,Androgen replacement therapy
12126565,121265651,1,I,20150523,20160217,20160229,20160229,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-014208,BRISTOL MYERS SQUIBB,,28,YR,,M,Y,62,KG,20160229,,CN,CN,CN,EFAVIRENZ,Delirium,121265651,OT,,,121265651,1,20150514,20150524,,,121265651,1,Acquired immunodeficiency syndrome
12127847,121278471,1,I,,20160217,20160229,20160229,EXP,,FR-GILEAD-2016-0199656,GILEAD,LORTHOLARY O ET AL. TENOFOVIR DF/EMTRICITABINE AND EFAVIRENZ COMBINATION THERAPY FOR HIV INFECTION IN PATIENTS TREATED FOR TUBERCULOSIS: THE ANRS 129 BKVIR TRIAL.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016?71(3):783-93,,,A,,Y,,,20160229,,MD,FR,FR,EFAVIRENZ,Bronchial obstruction;Immune reconstitution inflammatory syndrome,121278471,OT,,,,,,,,,121278471,1,HIV infection
12127891,121278911,1,I,,20160217,20160229,20160229,EXP,,FR-GILEAD-2016-0199655,GILEAD,LORTHOLARY O ET AL. TENOFOVIR DF/EMTRICITABINE AND EFAVIRENZ COMBINATION THERAPY FOR HIV INFECTION IN PATIENTS TREATED FOR TUBERCULOSIS: THE ANRS 129 BKVIR TRIAL.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016?71(3):783-93,,,A,,Y,,,20160229,,MD,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoma of central nervous system,121278911,OT,,,,,,,,,121278911,1,HIV infection
12127906,121279061,1,I,,20160217,20160229,20160229,EXP,,FR-GILEAD-2016-0199654,GILEAD,LORTHOLARY O ET AL. TENOFOVIR DF/EMTRICITABINE AND EFAVIRENZ COMBINATION THERAPY FOR HIV INFECTION IN PATIENTS TREATED FOR TUBERCULOSIS: THE ANRS 129 BKVIR TRIAL.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016?71(3):783-93,,,A,,Y,,,20160229,,MD,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Tuberculoma of central nervous system,121279061,OT,,,,,,,,,121279061,1,HIV infection
12129353,121293531,1,I,20130521,20130527,20160229,20160229,EXP,,MW-GILEAD-2013-0076855,GILEAD,,29,YR,A,M,Y,60.5,KG,20160229,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Cellulitis,121293531,HO,,,121293531,1,20130128,,,,121293531,1,Acquired immunodeficiency syndrome
12137617,121376171,1,I,,20160222,20160302,20160302,EXP,,ES-TEVA-638593ISR,TEVA,"FERNANDEZ-ALVAREZ R, GONZALEZ-RODRIGUEZ AP, RUBIO-CASTRO A, GONZALEZ ME, PAYER AR, ALONSO-GARCIA A, ET AL. BORTEZOMIB PLUS CHOP FOR THE TREATMENT OF HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA: CLINICAL EXPERIENCE IN THREE PATIENTS. LEUK-LYMPHOMA 2016?57(2):463-466.",39,YR,,M,Y,,,20160302,,OT,ES,ES,efavirenz,Anaemia;Cytomegalovirus chorioretinitis;Neutropenia;Peripheral sensory neuropathy;Progressive multifocal leukoencephalopathy;Sepsis;Thrombocytopenia;Viral haemorrhagic cystitis,121376171,DE,,,,,,,,,121376171,1,Plasmablastic lymphoma
12139939,121399391,1,I,,20160222,20160303,20160303,EXP,,GB-HETERO LABS LTD-1048603,HETERO,,49,YR,,M,Y,,,20160303,,OT,GB,GB,Efavirenz,Ankle fracture;Road traffic accident,121399391,HO,,,,,,,,,,,
12140970,121409701,1,I,20040125,20040315,20160303,20160303,EXP,,FR-009507513-2004-113821-NL,MERCK,,19,YR,,F,Y,53,KG,20160303,,OT,FR,FR,SUSTIVA,Abortion induced;Drug interaction;Pregnancy with implant contraceptive;Therapeutic response decreased,121409701,HO,,,121409701,1,200107,20040322,,,121409701,1,Contraception
12142962,121429621,1,I,,20160226,20160303,20160303,EXP,,US-GILEAD-2016-0201217,GILEAD,,51,YR,A,M,Y,,,20160303,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Mass,121429621,HO,,,,,,,,,121429621,1,HIV infection
12144135,121441351,1,I,,20160202,20160304,20160304,EXP,,GB-HETERO LABS LTD-1048675,HETERO,,,,,F,Y,,,20160304,,OT,GB,GB,Efavirenz,Drug resistance;Off label use;Virologic failure,121441351,OT,,,121441351,1,201111,,,,121441351,1,HIV infection
12144212,121442122,2,F,20151221,20160318,20160304,20160325,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-014561,BRISTOL MYERS SQUIBB,,49,YR,,M,Y,,,20160325,,CN,GB,GB,SUSTIVA,Ankle fracture;Ankle operation;Road traffic accident,121442122,HO,,,,,,,,,121442122,1,Product used for unknown indication
12145960,121459601,1,I,20130123,20130218,20160304,20160304,EXP,,FR-VIIV HEALTHCARE LIMITED-B0871259A,VIIV,,44,YR,,M,Y,57,KG,20160304,,MD,FR,FR,SUSTIVA,Acute coronary syndrome;Hypovolaemia,121459601,OT,,,121459601,1,20121002,,,,121459601,1,HIV infection
12154055,121540552,2,F,,20160317,20160307,20160325,EXP,,ES-CIPLA LTD.-2016ES01677,CIPLA,"PALACIOS R, PEREZ-HERNANDEZ IA, MARTINEZ MA, MAYORGA ML, GONZALEZ-DOMENECH CM, OMAR M, ET AL.,. EFFICACY AND SAFETY OF SWITCHING TO ABACAVIR/LAMIVUDINE (ABC/3TC) PLUS RILPIVIRINE (RPV) IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS ON HAART. EUR J CLIN MICROBIOL INFECT DIS. 2016",,,,,Y,,,20160325,,OT,ES,ES,Efavirenz,Virologic failure,121540552,OT,,,,,,,,,121540552,1,HIV infection
12154312,121543121,1,I,,20160223,20160307,20160307,EXP,,HT-HETERO LABS LTD-1048743,HETERO,,30,YR,,F,Y,,,20160307,,OT,HT,HT,Efavirenz,Anaemia;Exposure during pregnancy;Stillbirth;Tuberculosis,121543121,HO,,,121543121,1,20140923,,,,121543121,1,HIV infection
12154690,121546901,1,I,,20160224,20160307,20160307,EXP,,ZA-009507513-1602ZAF012732,MERCK,,,,,,Y,,,20160307,,OT,ZA,ZA,EFAVIRENZ,Drug-induced liver injury,121546901,OT,,,,,,,,,,,
12156246,121562461,1,I,201404,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009290,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Anaemia;Blood creatinine increased;CD4 lymphocytes decreased;Deafness;Dizziness;Haemorrhage;Headache;Renal failure;Viral load increased,121562461,OT,,,121562461,1,201404,20140623,,,121562461,1,Antiretroviral therapy
12156247,121562471,1,I,,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009295,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Blood creatine phosphokinase increased;CD4 lymphocytes abnormal;Confusional state;Decreased appetite;Dyspnoea;Fatigue;Jaundice;Rash;Weight decreased,121562471,HO,,,121562471,1,20140117,,,,121562471,1,Antiretroviral therapy
12156248,121562481,1,I,20140424,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009264,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Blood creatinine increased;CD4 lymphocytes decreased;Confusional state;Decreased appetite;Disturbance in attention;Dizziness;Dyspnoea;Fatigue;Haemoglobin decreased;Viral load increased;Weight decreased,121562481,HO,,,121562481,1,20140408,,,,121562481,1,Antiretroviral therapy
12156249,121562491,1,I,20150223,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009433,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Alanine aminotransferase abnormal;Blood creatinine increased;CD4 lymphocytes decreased;Rash,121562491,OT,,,121562491,1,20141230,,,,121562491,1,Antiretroviral therapy
12156250,121562501,1,I,,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009436,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Diarrhoea;Vomiting;Weight decreased,121562501,HO,,,121562501,1,20151012,,,,121562501,1,Antiretroviral therapy
12156252,121562521,1,I,,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009272,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Blood creatine phosphokinase increased;CD4 lymphocytes abnormal;Decreased appetite;Diarrhoea;Nausea;Viral load;Vomiting;Weight decreased,121562521,OT,,,121562521,1,2010,,,,121562521,1,Antiretroviral therapy
12156516,121565161,1,I,,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009281,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Blood creatine phosphokinase increased;CD4 lymphocytes abnormal;Dizziness;Haemoglobin decreased;Headache;Myalgia;Weight decreased,121565161,HO,,,121565161,1,20070107,20140430,,,,,
12156517,121565171,1,I,20140619,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009396,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Anaemia;Back pain;Blood creatinine increased;Decreased appetite;Dizziness;Dyspnoea;Oesophageal candidiasis;Weight decreased,121565171,HO,,,121565171,1,201303,,,,121565171,2,HIV infection
12156520,121565201,1,I,20140625,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009686,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,EFAVIRENZ MYLAN,Alanine aminotransferase increased;Blood creatine increased;CD4 lymphocytes decreased;Haemoglobin decreased;Ocular icterus;Vomiting,121565201,HO,,,121565201,1,20070705,,,,121565201,1,Antiretroviral therapy
12156702,121567021,1,I,20150722,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009701,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,EFAVIRENZ MYLAN 600 MG COMPRIM?S PELLICUL?S,Abdominal pain;Confusional state;Decreased appetite;Hallucination;Insomnia;Nausea;Psychotic disorder;Pyrexia;Vomiting,121567021,OT,,,121567021,1,20150713,20150727,,,121567021,1,Antiretroviral therapy
12156703,121567031,1,I,20140410,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009706,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,EFAVIRENZ MYLAN 600 MG COMPRIM?S PELLICUL?S,Anaemia;Blood creatine increased;Dizziness;Dyspnoea;Viral load,121567031,OT,,,121567031,1,20080730,20131230,,,121567031,1,Antiretroviral therapy
12156704,121567041,1,I,201403,20160224,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009710,MYLAN,,,,,,Y,,,20160307,,OT,ZA,ZA,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Blood creatine increased;CD4 lymphocytes decreased;Confusional state;Dyspnoea;Haemoglobin decreased;Rash;Skin exfoliation;Viral load;Weight decreased,121567041,HO,,,121567041,1,20130330,201403,,,,,
12156890,121568901,1,I,,20160226,20160307,20160307,EXP,,US-BMSGILMSD-2016-0201464,GILEAD,,54,YR,A,M,Y,,,20160307,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Hip arthroplasty,121568901,OT,,,121568901,1,201401,,,,121568901,1,HIV infection
12157583,121575831,1,I,,20160224,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01867,CIPLA,"PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L, PATEL F ET AL.,. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308,,OT,US,ZA,Efavirenz,Abdominal pain upper;Ataxia;Cogwheel rigidity;Dysarthria;Gait disturbance;Hypotonia;Intention tremor;Nervous system disorder;Urinary tract infection;Vomiting,121575831,HO,,,,,,,,,121575831,1,Perinatal HIV infection
12157589,121575891,1,I,,20160224,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01865,CIPLA,"ABRAMS E, PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L ET AL.,. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308,,OT,US,ZA,Efavirenz,Aggression;Conjunctivitis allergic;Drug level increased;Generalised tonic-clonic seizure;Pyrexia,121575891,OT,,,,,,,,,121575891,1,Perinatal HIV infection
12157591,121575911,1,I,,20160224,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01862,CIPLA,"ABRAMS E, PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L, ET AL.,. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308,,OT,US,ZA,Efavirenz,Abnormal behaviour;Drug level increased;Petit mal epilepsy,121575911,OT,,,,,,,,,121575911,1,HIV infection
12157605,121576051,1,I,,20160224,20160308,20160308,EXP,,US-CIPLA LTD.-2016US01861,CIPLA,"ABRAMS E, PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L ET AL. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC INFECTIOUS DISEASES. 2016?16 (56):1 TO 7",,,,,Y,,,20160308,,OT,US,ZA,Efavirenz,Drug level increased;Encephalitis;Generalised tonic-clonic seizure;Meningism;Pulmonary tuberculosis;Tonsillitis,121576051,HO,,,,,,,,,121576051,1,Perinatal HIV infection
12158992,121589921,1,I,20140405,20160224,20160308,20160308,EXP,,ZA-MYLANLABS-2016M1009282,MYLAN,,,,,,Y,,,20160308,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Deafness;Tinnitus,121589921,DS,,,,,,,,,121589921,1,Antiretroviral therapy
12160761,121607613,3,F,20160216,20160328,20160308,20160331,EXP,,BR-GILEAD-2016-0201948,GILEAD,,43,YR,A,M,Y,68,KG,20160331,,OT,BR,BR,EFAVIRENZ,Hepatic failure,121607613,DE,,,121607613,1,20151017,20160219,,,121607613,1,HIV infection
12161093,121610932,2,F,20160217,20160329,20160308,20160331,EXP,,UA-GILEAD-2016-0200699,GILEAD,,37,YR,A,F,Y,,,20160331,,MD,UA,UA,EFAVIRENZUM,Anaemia;Leukopenia;Nephropathy toxic;Pneumonia;Pulmonary tuberculosis,121610932,HO,,,121610932,1,20160127,20160219,,,121610932,1,Hepatitis C
12161166,121611661,1,I,,20100503,20160308,20160308,EXP,,CA-ABBVIE-10P-163-0641882-00,ABBVIE,"PFEFFER G, COTE H, MONTANER J, ET AL. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009 JUL?73:71-72.",52,YR,,M,Y,,,20160308,,MD,COUNTRY NOT SPECIFIED,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,121611661,OT,,,121611661,1,200802,200802,,,121611661,1,HIV infection
12165719,121657191,1,I,,20160303,20160309,20160309,EXP,,CA-BMSGILMSD-2016-0202001,GILEAD,,63,YR,A,F,Y,,,20160309,,CN,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Headache;Osteoporosis,121657191,OT,,,,,,,,,121657191,1,Product used for unknown indication
12166837,121668371,1,I,,20160229,20160310,20160310,EXP,,CN-CIPLA LTD.-2016CN02081,CIPLA,"LU H, XIAO H, XUE Y, GU S, WANG J, SUN H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCIENCE TRENDS. 2016?P1 TO P5",,,,,Y,,,20160310,,OT,CN,CN,Efavirenz,Anaemia;Drug resistance;Haemorrhage;Nightmare;Virologic failure,121668371,OT,,,,,,,,,121668371,1,HIV infection
12166849,121668491,1,I,,20160229,20160310,20160310,EXP,,CN-CIPLA LTD.-2016CN02083,CIPLA,"LU H, XIAO H, XUE Y, GU S, WANG J, SUN H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCIENCE TRENDS. 2016?P1 TO P5",,,,,Y,,,20160310,,OT,CN,CN,Efavirenz,Depression;Drug resistance;Haemorrhage;Hypoaesthesia;Insomnia;Virologic failure,121668491,OT,,,,,,,,,121668491,1,HIV infection
12166871,121668711,1,I,,20160229,20160310,20160310,EXP,,CN-CIPLA LTD.-2016CN02086,CIPLA,"LU H, XIAO H, XUE Y, GU S, WANG J, SUN H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCIENCE TRENDS. 2016?1 TO 5",,,,,Y,,,20160310,,OT,CN,CN,Efavirenz,Osteoporosis,121668711,OT,,,,,,,,,121668711,1,Antiretroviral therapy
12166886,121668861,1,I,,20160229,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02082,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310,,OT,ES,ES,Efavirenz,Hyperbilirubinaemia,121668861,OT,,,,,,,,,121668861,1,HIV infection
12166892,121668921,1,I,,20160229,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02084,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310,,OT,ES,ES,Efavirenz,Toxicity to various agents,121668921,OT,,,,,,,,,121668921,1,HIV infection
12166893,121668931,1,I,,20160229,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02112,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310,,OT,ES,ES,Efavirenz,Death,121668931,DE,,,,,,,,,121668931,1,HIV infection
12167073,121670731,1,I,,20160229,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02123,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310,,OT,ES,ES,Efavirenz,Hypophosphataemia,121670731,OT,,,,,,,,,121670731,1,HIV infection
12167078,121670781,1,I,,20160229,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02119,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310,,OT,ES,ES,Efavirenz,Osteoporosis,121670781,OT,,,,,,,,,121670781,1,HIV infection
12167082,121670821,1,I,,20160229,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02118,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310,,OT,ES,ES,Efavirenz,Nephrolithiasis,121670821,OT,,,,,,,,,121670821,1,HIV infection
12167116,121671161,1,I,,20160229,20160310,20160310,EXP,,ES-CIPLA LTD.-2016ES02125,CIPLA,"PEREZ-MOLINA JA, RUBIO R, RIVERO A, PASQUAU J, SUAREZ-LOZANO I, RIERA M ET AL.,. DUAL TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS LAMIVUDINE VERSUS TRIPLE TREATMENT WITH ATAZANAVIR-RITONAVIR PLUS TWO NUCLEOS(T)IDES IN VIROLOGICALLY STABLE PATIENTS WITH HIV-1 (SALT): 48 WEEK RESULTS FROM A RANDOMISED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET INFECT DIS. 2015?15:775 TO 784",,,,,Y,,,20160310,,OT,ES,ES,Efavirenz,Thrombocytopenia,121671161,OT,,,,,,,,,121671161,1,HIV infection
12169235,121692352,2,F,20160203,20160229,20160310,20160310,EXP,,FR-SA-2016SA042147,AVENTIS,,49,YR,A,F,Y,,,20160310,,OT,FR,FR,SUSTIVA,Diarrhoea;Electrocardiogram abnormal;Hypokalaemia,121692352,HO,,,121692352,1,201106,20160208,,,121692352,1,Ascites
12169549,121695491,1,I,20160229,20160304,20160310,20160310,EXP,,ZW-GILEAD-2016-0202475,GILEAD,,44,YR,A,F,Y,52,KG,20160310,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Weight decreased,121695491,OT,,,121695491,1,20150603,20150824,,,121695491,1,HIV infection
12169701,121697011,1,I,20150526,20160302,20160310,20160310,EXP,,GB-GILEAD-2016-0202208,GILEAD,,74,YR,E,M,Y,112,KG,20160310,,MD,GB,GB,EFAVIRENZ,Chest pain;Palpitations,121697011,HO,,,121697011,1,20120410,,,,121697011,1,HIV infection
12170481,121704811,1,I,,20160229,20160311,20160311,EXP,,US-CIPLA LTD.-2016US02145,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160311,,OT,US,US,Efavirenz,Blood creatine phosphokinase abnormal,121704811,OT,,,,,,,,,121704811,1,HIV infection
12170488,121704881,1,I,,20160229,20160311,20160311,EXP,,US-CIPLA LTD.-2016US02135,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL O F MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160311,,MD,US,US,Efavirenz,Glycosuria;Renal impairment,121704881,OT,,,,,,,,,121704881,1,HIV infection
12170559,121705591,1,I,,20160229,20160311,20160311,EXP,,US-CIPLA LTD.-2016US02157,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160311,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121705591,OT,,,,,,,,,121705591,1,HIV infection
12171229,121712291,1,I,,20160301,20160311,20160311,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-016765,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160311,,OT,COUNTRY NOT SPECIFIED,TH,EFAVIRENZ,Hypotension;Labelled drug-drug interaction medication error;Peripheral ischaemia,121712291,OT,,,,,,,,,121712291,1,HIV infection
12173874,121738741,1,I,,20151013,20160314,20160314,PER,,"US-GLENMARK PHARMACEUTICALS INC, USA.-2015GMK020177",GLENMARK,"MURPHY R A, GOUNDER L, MANZINI T C, RAMDIAL P K, CASTILLA C, MOOSA M-Y S. CHALLENGES IN THE MANAGEMENT OF DISSEMINATED PROGRESSIVE HISTOPLASMOSIS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS IN RESOURCE-LIMITED SETTINGS.. OPEN FORUM INFECTIOUS DISEASES.. 2015?2(1)",35,YR,,M,Y,,,20160314,,MD,US,US,EFAVIRENZ,Off label use;Therapeutic response unexpected,,,,,,,,,,,121738741,1,Histoplasmosis
12174409,121744091,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02137,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL O F MEDICINE. 2015?373(8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Haemoglobin abnormal,121744091,OT,,,,,,,,,121744091,1,HIV infection
12174424,121744241,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02155,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Infection;Treatment noncompliance;Virologic failure,121744241,OT,,,,,,,,,121744241,1,HIV infection
12174433,121744331,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02156,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121744331,OT,,,,,,,,,121744331,1,HIV infection
12174438,121744381,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02178,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373(8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Rhabdomyolysis,121744381,OT,,,,,,,,,121744381,1,HIV infection
12174440,121744401,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02158,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W, MARKS K, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373:705-713",,,,,Y,,,20160313,,MD,US,US,Efavirenz,Disease recurrence,121744401,OT,,,,,,,,,121744401,1,Hepatitis C
12174441,121744411,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02161,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W, MARKS K, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373:705-713",,,,,Y,,,20160313,,MD,US,US,Efavirenz,Disease recurrence,121744411,OT,,,,,,,,,121744411,1,Hepatitis C
12174447,121744471,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02166,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121744471,OT,,,,,,,,,121744471,1,HIV infection
12174448,121744481,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02169,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Disease recurrence;Virologic failure,121744481,OT,,,,,,,,,121744481,1,HIV infection
12174449,121744491,1,I,,20160229,20160313,20160313,EXP,,US-CIPLA LTD.-2016US02171,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER WJ, ET AL.,. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015?373 (8):705 TO 713",,,,,Y,,,20160313,,OT,US,US,Efavirenz,Hepatitis C;Virologic failure,121744491,OT,,,,,,,,,121744491,1,HIV infection
12177888,121778882,2,F,,20160316,20160314,20160323,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-018229,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20160323,,OT,JP,JP,EFAVIRENZ,Lactic acidosis,121778882,OT,,,,,,,,,121778882,1,HIV infection
12181720,121817201,1,I,,20160307,20160315,20160315,EXP,,IN-GILEAD-2016-0203057,GILEAD,"PAIK S, PAL A, SEN S, PRAMANICK N, TRIPHATHI SK. A SUSPECTED CASE OF EFAVIRENZ-INDUCED STEVENS-JOHNSON SYNDROME.. DRUG SAFETY-CASE REPORTS.. 2015?2 (1):PP 1-5",23,YR,A,F,Y,,,20160315,,OT,IN,IN,EFAVIRENZ,Stevens-Johnson syndrome,121817201,OT,,,,,,,,,121817201,1,HIV infection
12181778,121817781,1,I,20160203,20160229,20160315,20160315,EXP,AN20160138 (0),FR-VALIDUS PHARMACEUTICALS LLC-FR-2016VAL000478,VALIDUS,,49,YR,,F,Y,,,20160315,,OT,FR,FR,SUSTIVA,Diarrhoea;Electrocardiogram abnormal;Hypokalaemia,121817781,HO,,,121817781,1,201106,20160208,,,121817781,1,Ascites
12181908,121819081,1,I,20110911,20160218,20160315,20160315,PER,,US-GILEAD-2016-0199709,GILEAD,,44,YR,A,M,Y,107,KG,20160315,,MD,US,US,SUSTIVA,Drug ineffective;Hepatitis B DNA increased,121819081,OT,,,,,,,,,121819081,1,Hepatitis B
12183825,121838251,1,I,,20160303,20160316,20160316,EXP,,IT-CIPLA LTD.-2016IT02397,CIPLA,"CALCAGNO A, MONTRUCCHIO C, CAPETTI A, GUARALDI G, CENDERELLO G, CALZA L ET AL.,. RALTEGRAVIR PLUS NEVIRAPINE AS MAINTENANCE ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS: SAFETY, EFFICACY AND PHARMACOKINETICS. CURRENT HIV RESEARCH. 2016?14 (1):54 TO 60",,,,,Y,,,20160316,,OT,IT,IT,Efavirenz,Chronic kidney disease,121838251,OT,,,,,,,,,121838251,1,HIV infection
12183908,121839081,1,I,,20160303,20160316,20160316,EXP,,IT-CIPLA LTD.-2016IT02400,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160316,,OT,IT,BI,Efavirenz,Treatment noncompliance;Viral load increased,121839081,OT,,,,,,,,,121839081,1,Antiretroviral therapy
12185376,121853761,1,I,,20160309,20160316,20160316,EXP,,BR-MYLANLABS-2016M1011056,MYLAN,"GOIS L, BADARO R, SCHOOLEY R, GRASSI MF. IMMUNE RESPONSE TO LEISHMANIA ANTIGENS IN AN AIDS PATIENT WITH MUCOCUTANEOUS LEISHMANIASIS AS A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS): A CASE REPORT. BMC-INFECT-DIS 2015?15(38):38.",,,,,Y,,,20160316,,OT,BR,BR,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Mucocutaneous leishmaniasis,121853761,HO,,,,,,,,,121853761,1,HIV infection
12186136,121861361,1,I,,20160303,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02399,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160317,,OT,IT,BI,Efavirenz,Drug level decreased;Treatment noncompliance,121861361,OT,,,,,,,,,121861361,1,Antiretroviral therapy
12186142,121861421,1,I,,20160303,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02402,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160317,,OT,IT,BI,Efavirenz,Virologic failure,121861421,OT,,,,,,,,,121861421,1,Antiretroviral therapy
12186153,121861531,1,I,,20160303,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02420,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2014?79 (5):801 TO 808",,,,,Y,,,20160317,,OT,IT,BI,Efavirenz,Drug resistance;Virologic failure,121861531,OT,,,,,,,,,121861531,1,Antiretroviral therapy
12186169,121861691,1,I,,20160303,20160317,20160317,EXP,,IT-CIPLA LTD.-2016IT02422,CIPLA,"MOTTA I, CALCAGNO A, MILIA MG, ROSTAGNO R, SIMIELE M, LIBANORE V ET AL.,. DRIED PLASMA/BLOOD SPOTS FOR MONITORING ANTIRETROVIRAL TREATMENT EFFICACY AND PHARMACOKINETICS: A CROSS-SECTIONAL STUDY IN RURAL BURUNDI. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2016?79 (5):801 TO 808",,,,,Y,,,20160317,,OT,IT,BI,Efavirenz,Drug resistance;Virologic failure,121861691,OT,,,,,,,,,121861691,1,HIV infection CDC category A
12187169,121871691,1,I,20140902,20141008,20160317,20160317,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2014008741,VIIV,,,,,,Y,,,20160317,,MD,UG,UG,Efavirenz,Bladder outlet obstruction;Glomerulonephritis,121871691,HO,,,121871691,1,20140811,20140909,,,121871691,1,HIV infection
12188132,121881321,1,I,,20160314,20160317,20160317,EXP,,RU-GLAXOSMITHKLINE-RU2016GSK037432,GLAXOSMITHKLINE,,,,,M,Y,,,20160317,,CN,RU,RU,STOCRIN (EFAVIRENZ),Abnormal faeces;Autonomic nervous system imbalance;Back pain;Biliary dyskinesia;Chromaturia;Constipation;Daydreaming;Dizziness;Fatigue;Flatulence;Influenza like illness;Irritability;Irritable bowel syndrome;Nausea;Oral disorder;Poisoning,121881321,OT,,,,,,,,,121881321,1,HIV infection
12188441,121884411,1,I,201603,20160311,20160317,20160317,EXP,,US-BMSGILMSD-2016-0203264,GILEAD,,44,YR,A,M,Y,,,20160317,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood glucose increased;Hypertension,121884411,HO,,,,,,,,,121884411,1,HIV infection
12189586,121895861,1,I,,20160308,20160318,20160318,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-018797,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160318,,OT,US,US,SUSTIVA,Drug hypersensitivity,,,,,,,,,,,121895861,1,Product used for unknown indication
12189889,121898891,1,I,,20160304,20160318,20160318,EXP,,US-CIPLA LTD.-2016US02507,CIPLA,"RAHANGDALE M, CATES J, POTTER J, BADELL ML, SEIDMAN D, MILLER ES ET AL. INTEGRASE INHIBITORS IN LATE PREGNANCY AND RAPID HIV VIRAL LOAD REDUCTION. AMERICAN JOURNAL OF OBSTETRICS + GYNECOLOGY. 2016?214:385 E1 TO E7",,,,,Y,,,20160318,,MD,US,US,Efavirenz,Foetal exposure during pregnancy;Upper respiratory tract infection,121898891,OT,,,,,,,,,,,
12189916,121899161,1,I,,20160304,20160318,20160318,EXP,,US-CIPLA LTD.-2016US02509,CIPLA,"RAHANGDALE M, CATES J, POTTER J, BADELL ML, SEIDMAN D, MILLER ES ET AL. INTEGRASE INHIBITORS IN LATE PREGNANCY AND RAPID HIV VIRAL LOAD REDUCTION. AMERICAN JOURNAL OF OBSTETRICS + GYNECOLOGY. 2016?214:385 E1 TO E7",,,,,Y,,,20160318,,MD,US,US,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Foetal exposure during pregnancy;Hyperbilirubinaemia,121899161,OT,,,,,,,,,,,
12190823,121908231,1,I,,20160314,20160318,20160318,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2016GSK037432,VIIV,,,,,M,Y,,,20160318,,CN,RU,RU,STOCRIN (EFAVIRENZ),Abnormal faeces;Autonomic nervous system imbalance;Back pain;Biliary dyskinesia;Chromaturia;Constipation;Daydreaming;Dizziness;Fatigue;Flatulence;Influenza like illness;Irritability;Irritable bowel syndrome;Nausea;Oral disorder;Poisoning,121908231,OT,,,,,,,,,121908231,1,HIV infection
12193749,121937491,1,I,,20160308,20160321,20160321,EXP,,US-CIPLA LTD.-2016UG02581,CIPLA,"KOSS CA, NATUREEBA P, NYAFWONO D, PLENTY A, MWESIGWA J, NZARUBARA B ET AL.,. FOOD INSUFFICIENCY IS ASSOCIATED WITH LACK OF SUSTAINED VIRAL SUPPRESSION AMONG HIV-INFECTED PREGNANT AND BREASTFEEDING UGANDAN WOMEN. J ACQUIR IMMUNE DEFIC SYNDR. 2016?71 (3):310 TO 315",,,,,Y,,,20160321,,OT,US,UG,Efavirenz,Exposure during breast feeding;Foetal exposure during pregnancy;HIV infection,121937491,OT,,,,,,,,,,,
12193754,121937541,1,I,,20160308,20160321,20160321,EXP,,US-CIPLA LTD.-2016US02574,CIPLA,"THIO CL, SMEATON L, HOLLABAUGH K, SAULYNAS M, HWANG H, SARAVANAN S ET AL.,. COMPARISON OF HBV-ACTIVE HAART REGIMENS IN AN HIV-HBV MULTINATIONAL COHORT: OUTCOMES THROUGH 144 WEEKS. AIDS. 2015?29:1173 TO 1182",,,,,Y,,,20160321,,CN,US,US,Efavirenz,Pneumonia bacterial,121937541,DE,,,,,,,,,121937541,1,Hepatitis B
12193755,121937551,1,I,,20160308,20160321,20160321,EXP,,US-CIPLA LTD.-2016UG02579,CIPLA,"KOSS CA, NATUREEBA P, NYAFWONO D, PLENTY A, MWESIGWA J, NZARUBARA B ET AL.,. FOOD INSUFFICIENCY IS ASSOCIATED WITH LACK OF SUSTAINED VIRAL SUPPRESSION AMONG HIV-INFECTED PREGNANT AND BREASTFEEDING UGANDAN WOMEN. J ACQUIR IMMUNE DEFIC SYNDR. 2016?71 (3):310 TO 315",,,,,Y,,,20160321,,OT,US,UG,Efavirenz,Exposure during breast feeding;Foetal exposure during pregnancy;HIV infection,121937551,OT,,,,,,,,,,,
12195166,121951661,1,I,,20160310,20160321,20160321,EXP,,CH-CIPLA LTD.-2016CH02709,CIPLA,"GUNTHARD HF, YANG WL, KOUYOS RD, SCHERRER AU, BONI J, SHAH C, ET AL.,. ASSESSING EFFICACY OF DIFFERENT NUCLEOS(T)IDE BACKBONES IN NNRTI-CONTAINING REGIMENS IN THE SWISS HIV COHORT STUDY. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?70:3323 TO 3331",,,,,Y,,,20160321,,OT,CH,CH,Efavirenz,Virologic failure,121951661,OT,,,,,,,,,121951661,1,HIV infection
12196779,121967792,2,F,20160113,20160321,20160321,20160325,EXP,,UG-GILEAD-2016-0197688,GILEAD,,56,YR,A,F,Y,55,KG,20160325,,MD,UG,UG,EFAVIRENZ,Cystocele;Urinary tract infection,121967792,HO,,,121967792,1,20121115,,,,121967792,1,HIV infection
12196850,121968501,1,I,,20160315,20160321,20160321,EXP,,US-GILEAD-2016-0204078,GILEAD,,59,YR,A,M,Y,,,20160321,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Central nervous system lesion;Toxoplasmosis,121968501,HO,,,,,,,,,121968501,1,HIV infection
12200868,122008681,1,I,201602,20160317,20160322,20160322,EXP,,US-BMSGILMSD-2016-0204507,GILEAD,,41,YR,A,M,Y,,,20160322,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,122008681,OT,,,,,,,,,122008681,1,HIV infection
12203023,122030232,2,F,,20160310,20160323,20160329,EXP,,US-009507513-1603USA008975,MERCK,,58,YR,,F,Y,,,20160329,,CN,US,US,EFAVIRENZ,Drug ineffective,122030232,OT,,,,,,,,,122030232,2,HIV infection
12209496,122094961,1,I,,20160301,20160324,20160324,EXP,,US-GILEAD-2016-0201984,GILEAD,,52,YR,A,M,Y,,,20160324,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Back pain;Renal disorder,122094961,OT,,,,,,,,,122094961,1,HIV infection
12209859,122098591,1,I,,20160314,20160325,20160325,EXP,,US-CIPLA LTD.-2016US02822,CIPLA,"MIKULA JM, MANION MM, MALDARELLI F, SUAREZ LM, NORMAN-WHEELER JF, OBER AG, ET AL.,. TENOFOVIR ALAFENAMIDE AS PART OF A SALVAGE REGIMEN IN A PATIENT WITH MULTI-DRUG RESISTANT HIV AND TENOFOVIR DF-ASSOCIATED RENAL TUBULOPATHY. ANTIVIRAL THERAPY. 2016",,,,,Y,,,20160325,,,US,US,Efavirenz,Acute kidney injury;Drug resistance;Dyslipidaemia;Lipodystrophy acquired;Neuropathy peripheral;Treatment failure,122098591,OT,,,122098591,11,201408,,,,122098591,1,HIV infection
12209958,122099581,1,I,,20160315,20160325,20160325,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-021595,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160325,,CN,US,US,SUSTIVA,Death,122099581,OT,,,,,,,,,122099581,1,Acquired immunodeficiency syndrome
12210242,122102421,1,I,20160310,,20160324,20160324,DIR,,,,,56,YR,,M,N,,,20160322,N,,US,,SUSTIVA,Rash,,,,,,,,,,,,,
12211624,122116241,1,I,,20160310,20160325,20160325,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-022907,BRISTOL MYERS SQUIBB,,58,YR,,F,Y,,,20160325,,OT,US,US,EFAVIRENZ,Drug ineffective,122116241,OT,,,,,,,,,122116241,1,HIV infection
12212729,122127291,1,I,,20160317,20160328,20160328,EXP,,ES-CIPLA LTD.-2016ES03023,CIPLA,"PALACIOS R, PEREZ-HERNANDEZ IA, MARTINEZ MA, MAYORGA ML, GONZALEZ-DOMENECH CM, OMAR M, ET AL.,. EFFICACY AND SAFETY OF SWITCHING TO ABACAVIR/LAMIVUDINE (ABC/3TC) PLUS RILPIVIRINE (RPV) IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS ON HAART. EUR J CLIN MICROBIOL INFECT DIS. 2016",,,,,Y,,,20160328,,OT,ES,ES,Efavirenz,Nephropathy toxic,122127291,OT,,,,,,,,,122127291,1,HIV infection
12213462,122134621,1,I,,20160314,20160328,20160328,EXP,,BR-LUPIN PHARMACEUTICALS INC.-2016-01124,LUPIN,"RIOS GRASSI M, GOIS L, BADARO R, SCHOOLEY R. IMMUNE RESPONSE TO LEISHMANIA ANTIGENS IN AN AIDS PATIENT WITH MUCOCUTANEOUS LEISHMANIASIS AS A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS): A CASE REPORT. BMC INFECTIOUS DISEASES. 2015?15 (38):1-7.",29,YR,,M,Y,,,20160328,,OT,BR,BR,Efavirenz,Immune reconstitution inflammatory syndrome;Mucocutaneous leishmaniasis,122134621,OT,,,,,,,,,122134621,1,HIV infection
12214114,122141141,1,I,,20160311,20160328,20160328,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-019880,BRISTOL MYERS SQUIBB,"GOOD BL, GOMES DC,  FULCO PP. AN UNEXPECTED INTERACTION BETWEEN WARFARIN AND COBICISTAT-BOOSTED ELVITEGRAVIR. AIDS. 2015?29:985-6",42,YR,,M,Y,,,20160328,,MD,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Anticoagulation drug level below therapeutic;Labelled drug-drug interaction medication error,,,,,,,,,,,122141141,1,Product used for unknown indication
12219433,122194331,1,I,20160202,20160325,20160329,20160329,EXP,,ZA-GILEAD-2016-0205750,GILEAD,,25,YR,A,F,Y,65,KG,20160329,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastritis,122194331,HO,,,122194331,1,20151217,,,,122194331,1,HIV infection
12223660,122236601,1,I,,20160322,20160330,20160330,EXP,,GB-MYLANLABS-2016M1012573,MYLAN,,,,,,Y,,,20160330,,OT,GB,GB,EFAVIRENZ,Death,122236601,DE,,,,,,,,,122236601,1,Product used for unknown indication
12224818,122248181,1,I,,20160321,20160331,20160331,EXP,,GB-HETERO LABS LTD-1050017,HETERO,,43,YR,,M,Y,,,20160331,,OT,GB,GB,EFAVIRENZ\ EMTRICITABINE\TENOFOVIR,Cerebrovascular accident;Cognitive disorder;Depression;Fatigue;Hypokinesia;Intentional self-injury,122248181,OT,,,,,,,,,122248181,1,Product used for unknown indication
12225303,122253031,1,I,,20160329,20160331,20160331,EXP,,GB-GLAXOSMITHKLINE-GB2016GSK043588,GLAXOSMITHKLINE,,,,,M,Y,,,20160331,,CN,GB,GB,SUSTIVA,Lower respiratory tract infection,122253031,OT,,,,,,,,,122253031,1,Product used for unknown indication
12225460,122254601,1,I,,20160329,20160331,20160331,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK043588,VIIV,,,,,M,Y,,,20160331,,CN,GB,GB,SUSTIVA,Lower respiratory tract infection,122254601,OT,,,,,,,,,122254601,1,Product used for unknown indication
4116412,41164123,3,F,20040322,20160202,20040331,20160202,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12543211,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160202,,MD,FR,FR,SUSTIVA,Abortion induced;Pregnancy with implant contraceptive,41164123,OT,,,41164123,1,20031117,,,,41164123,1,HIV infection
5958680,59586803,3,F,20051218,20160107,20060111,20160112,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13232228,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20160112,,CN,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy,59586803,OT,,,59586803,1,20051002,20051002,,,59586803,1,Antiretroviral therapy
6019176,60191763,3,F,20060317,20160225,20060405,20160225,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13322631,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20160225,,CN,US,ZA,EFAVIRENZ,Abortion induced;Pregnancy,60191763,OT,,,60191763,1,2005,20060316,,,60191763,1,Antiretroviral therapy
6568945,65689455,5,F,,20160225,20080304,20160225,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099824,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160225,,OT,US,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689455,OT,,,,,,,,,65689455,1,Product used for unknown indication
6568951,65689515,5,F,,20160225,20080304,20160225,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099949,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160225,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689515,OT,,,,,,,,,65689515,1,Product used for unknown indication
6568952,65689525,5,F,,20160225,20080304,20160225,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099923,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160225,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689525,OT,,,,,,,,,65689525,1,Product used for unknown indication
6568953,65689535,5,F,,20160225,20080304,20160225,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099964,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160225,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689535,OT,,,,,,,,,65689535,1,Product used for unknown indication
6592563,65925633,3,F,,20160202,20080325,20160202,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14121487,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160202,,OT,GB,GB,EFAVIRENZ,Drug interaction;Pregnancy with implant contraceptive,65925633,OT,,,65925633,3,2006,,,,65925633,1,Retroviral infection
7117171,71171718,8,F,,20160218,20090917,20160302,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20160302,,CN,US,US,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,71171718,OT,,,71171718,9,200802,,,,71171718,1,HIV infection
7155921,71559218,8,F,,20160128,20091022,20160201,EXP,,CA-ROCHE-663583,ROCHE,"PFEFFER G, PFEFFER G, COTE H, MONTANER J, LI C, JITRATKOSOL M AND MEZEI M. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY 2009 JUL 07?73 (1):71-72.",52,YR,,M,Y,,,20160201,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,71559218,OT,,,,,,,,,71559218,1,HIV infection
7230481,72304812,2,F,2008,20160112,20091224,20160115,EXP,,GB-GILEAD-2009-0026167,GILEAD,,33,YR,A,F,Y,,,20160115,,OT,GB,GB,EFAVIRENZ;SUSTIVA,Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,72304812,OT,,,72304812,5,20040811,20070716,,,72304812,1,HIV infection
7302622,730262225,25,F,,20160218,20100302,20160219,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20160219,,CN,US,CA,SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262225,OT,,,,,,,,,730262225,1,HIV infection
7476212,74762124,4,F,,20160218,20100715,20160228,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-15190788,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20160228,,CN,US,CA,SUSTIVA,Depression;Drug interaction,74762124,OT,,,,,,,,,74762124,1,Product used for unknown indication
7512166,75121664,4,F,,20160324,20100730,20160324,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-15212632,BRISTOL MYERS SQUIBB,,,,,F,Y,2.7,KG,20160324,,OT,BR,BR,EFAVIRENZ,Congenital melanocytic naevus;Foetal exposure during pregnancy;Patent ductus arteriosus,75121664,OT,,,75121664,1,20021107,20021106,,,75121664,1,Product used for unknown indication
7512167,75121673,3,F,,20160324,20100730,20160324,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-15212707,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160324,,OT,AR,AR,EFAVIRENZ,Congenital Horner's syndrome;Foetal exposure during pregnancy,75121673,CA,,,75121673,1,20021205,20050111,,,75121673,1,Product used for unknown indication
7680832,76808324,4,F,,20160202,20101123,20160202,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15394901,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20160202,,OT,GB,US,EFAVIRENZ,Abortion induced;Drug interaction;Pregnancy with implant contraceptive,76808324,OT,,,,,,,,,76808324,1,Antiretroviral therapy
8159073,815907314,14,F,201108,20160125,20110927,20160201,EXP,,GB-GILEAD-2011-0044197,GILEAD,,1,DY,N,M,Y,,,20160201,,CN,GB,GB,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital teratoma;Conjunctival haemorrhage;Cryptorchism;Facial paresis;Foetal exposure during pregnancy;Respiratory distress,815907314,CA,,,815907314,1,20100915,20110913,,,815907314,1,HIV infection
8169345,81693452,2,F,20100327,20151119,20111005,20160118,EXP,,US-GILEAD-2010-0029365,GILEAD,,26,YR,A,F,Y,,,20160118,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Caesarean section;Maternal exposure during pregnancy;Premature delivery;Twin pregnancy,81693452,OT,,,81693452,1,20100518,20100518,,,81693452,1,HIV infection
8383331,83833314,4,F,20101120,20160114,20120201,20160120,EXP,GB-MHRA-ADR 21453021,GB-GILEAD-2011-0044189,GILEAD,,37,YR,A,F,Y,,,20160120,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Headache;Live birth;Maternal exposure during pregnancy,83833314,OT,,,83833314,1,20100301,20110913,,,83833314,1,HIV infection
8575217,85752175,5,F,2012,20160215,20120523,20160223,EXP,,GB-VIIV HEALTHCARE LIMITED-B0804044A,VIIV,,43,YR,,M,Y,94,KG,20160223,,CN,GB,GB,Efavirenz,Head discomfort;Jaundice;Off label use;Sleep disorder,85752175,OT,,,85752175,1,2010,20120326,,,85752175,1,Immunosuppression
8745672,87456725,5,F,20120603,20160203,20120826,20160208,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-16861148,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,46.89,KG,20160208,,CN,GB,GB,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Off label use,87456725,OT,,,,,,,,,87456725,1,HIV infection
8949679,89496793,3,F,,20160315,20121206,20160318,EXP,,GB-009507513-1109GBR00053,MERCK,,32,YR,,F,Y,,,20160318,,CN,US,GB,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy;Off label use;Premature delivery;Premature rupture of membranes;Uterine leiomyoma,89496793,OT,,,,,,,,,89496793,1,HIV infection
9031911,90319113,3,F,20080918,20160316,20130125,20160316,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17316886,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160316,,CN,US,FR,SUSTIVA,Cholestasis;Gestational diabetes;Live birth;Maternal exposure during pregnancy;Off label use,90319113,OT,,,90319113,1,20060615,,,,90319113,1,HIV infection
9139068,91390683,3,F,,20160316,20130305,20160316,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-17423922,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,,,20160316,,MD,PT,PT,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy;Off label use,91390683,OT,,,91390683,1,201202,,,,91390683,1,HIV infection
9344804,93448044,4,F,20110705,20160316,20130612,20160316,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-18994129,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20160316,,MD,PT,PT,EFAVIRENZ,Dizziness;Inappropriate schedule of drug administration;Maternal exposure during pregnancy;Off label use;Premature delivery;Twin pregnancy;Viral load increased,93448044,OT,,,93448044,1,2011,,,,93448044,1,HIV infection
9720115,97201152,2,F,20130801,20160203,20131128,20160208,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-19839349,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20160208,,CN,ES,ES,SUSTIVA,Nephrolithiasis;Off label use,97201152,OT,,,97201152,1,20110418,,,,97201152,1,HIV infection
9808689,98086894,4,F,20130611,20160316,20140110,20160316,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18766808,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20160316,,OT,GB,GB,EFAVIRENZ,Abnormal dreams;Drug level increased;Maternal exposure during pregnancy;Neurotoxicity;Normal newborn;Off label use;Sleep disorder,98086894,OT,,,98086894,1,20121212,,,,98086894,1,Antiretroviral therapy
